0001613103-24-000058.txt : 20240523 0001613103-24-000058.hdr.sgml : 20240523 20240523064745 ACCESSION NUMBER: 0001613103-24-000058 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240523 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240523 DATE AS OF CHANGE: 20240523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Medtronic plc CENTRAL INDEX KEY: 0001613103 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 FISCAL YEAR END: 0426 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36820 FILM NUMBER: 24975165 BUSINESS ADDRESS: STREET 1: 20 ON HATCH, LOWER HATCH STREET CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: 01135314381700 MAIL ADDRESS: STREET 1: 20 ON HATCH, LOWER HATCH STREET CITY: DUBLIN STATE: L2 ZIP: 2 FORMER COMPANY: FORMER CONFORMED NAME: Medtronic Ltd DATE OF NAME CHANGE: 20150112 FORMER COMPANY: FORMER CONFORMED NAME: Medtronic Holdings Ltd DATE OF NAME CHANGE: 20140711 FORMER COMPANY: FORMER CONFORMED NAME: Kalani I Ltd DATE OF NAME CHANGE: 20140709 8-K 1 mdt-20240523.htm 8-K mdt-20240523
0001613103Medtronic plcD02 XH02false00016131032024-05-232024-05-230001613103us-gaap:CommonStockMember2024-05-232024-05-230001613103mdt:SeniorNotes2019Due2025Member2024-05-232024-05-230001613103mdt:SeniorNotes2020Due2025Member2024-05-232024-05-230001613103mdt:SeniorNotesDue2025Member2024-05-232024-05-230001613103mdt:SeniorNotes2019Due2027Member2024-05-232024-05-230001613103mdt:SeniorNotes2020Due2028Member2024-05-232024-05-230001613103mdt:SeniorNotesDue2028Member2024-05-232024-05-230001613103mdt:SeniorNotes2019Due20311.625PercentMember2024-05-232024-05-230001613103mdt:SeniorNotes2019Due20311.00PercentMember2024-05-232024-05-230001613103mdt:SeniorNotesDue2031Member2024-05-232024-05-230001613103mdt:SeniorNotes2020Due2032Member2024-05-232024-05-230001613103mdt:SeniorNotesDue2034Member2024-05-232024-05-230001613103mdt:SeniorNotes2019Due20392.250PercentMember2024-05-232024-05-230001613103mdt:SeniorNotes2019Due20391.50PercentMember2024-05-232024-05-230001613103mdt:SeniorNotes2020Due2040Member2024-05-232024-05-230001613103mdt:SeniorNotes2019Due2049Member2024-05-232024-05-230001613103mdt:SeniorNotes2020Due2050Member2024-05-232024-05-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
_____________________________ 
FORM 8-K
 _____________________________ 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 23, 2024
 _____________________________ 
Medtronic plc
(Exact name of Registrant as Specified in its Charter)
  _____________________________ 
 
Ireland 1-36820 98-1183488
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)

20 On Hatch, Lower Hatch Street
Dublin 2, Ireland
(Address of principal executive offices) (Zip Code)
+353 1 438-1700
(Registrant’s telephone number, including area code)
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))













Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange
0.250% Senior Notes due 2025MDT/25New York Stock Exchange
0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange
2.625% Senior Notes due 2025MDT/25BNew York Stock Exchange
1.125% Senior Notes due 2027MDT/27New York Stock Exchange
0.375% Senior Notes due 2028MDT/28New York Stock Exchange
3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange
1.625% Senior Notes due 2031MDT/31New York Stock Exchange
1.000% Senior Notes due 2031MDT/31ANew York Stock Exchange
3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange
0.750% Senior Notes due 2032MDT/32New York Stock Exchange
3.375% Senior Notes due 2034MDT/34New York Stock Exchange
2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange
1.500% Senior Notes due 2039MDT/39BNew York Stock Exchange
1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange
1.750% Senior Notes due 2049MDT/49New York Stock Exchange
1.625% Senior Notes due 2050MDT/50New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.





Item 2.02.Results of Operations and Financial Condition

On May 23, 2024, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its full year and fourth quarter fiscal year 2024 financial results. A copy of the Medtronic financial results press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
 
Item 9.01.Exhibits
(d) List of Exhibits
Exhibit Number  Description
  
104
Cover Page Interactive Data File (embedded with the Inline XBRL document).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
   Medtronic plc
  By /s/ Karen L. Parkhill
Date: May 23, 2024   Karen L. Parkhill
   Executive Vice President and Chief Financial Officer







EXHIBIT INDEX
Exhibit Number  Description
  
104
Cover Page Interactive Data File (embedded with the Inline XBRL document).



EX-99 2 exhibit991-fy24q4earningsr.htm EX-99 Document

Exhibit 99.1
image_0a.jpg

NEWS RELEASE
 
Contacts:
  
 Erika Winkels   Ryan Weispfenning
 Public Relations  Investor Relations
 +1-763-526-8478  +1-763-505-4626

FOR IMMEDIATE RELEASE

Medtronic reports full year and fourth quarter
fiscal 2024 financial results;
announces dividend increase

Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Heart; gaining momentum as company enters new product cycles across many high-growth markets

DUBLIN – May 23, 2024 – Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter (Q4) and fiscal year 2024 (FY24), which ended April 26, 2024.

Key Highlights
Q4 revenue of $8.6 billion increased 0.5% as reported and 5.4% organic
Q4 GAAP diluted earnings per share (EPS) of $0.49; non-GAAP diluted EPS of $1.46
1


FY24 revenue of $32.4 billion increased 3.6% as reported and 5.2% organic
FY24 GAAP diluted EPS of $2.76; non-GAAP diluted EPS of $5.20
FY24 cash from operations of $6.8 billion increased 12%; FY24 free cash flow of $5.2 billion increased 14%
Company returned $5.5 billion to shareholders in FY24, including $1.6 billion through net share repurchases in Q4
Company issues FY25 guidance
Dividend increased to $0.70 per share quarterly, annual $2.80 per share; 47th consecutive year of dividend increases
Received U.S. FDA approval for Evolut™ FX+ TAVR system and Inceptiv™ closed-loop spinal cord stimulator; received China National Medical Products Administration (NMPA) approval for Symplicity Spyral™ renal denervation system; submitted Affera Sphere-9™ ablation catheter and Simplera Sync™ CGM to U.S. FDA seeking approval

Q4 Financial Results
Medtronic reported Q4 worldwide revenue of $8.589 billion, an increase of 0.5% as reported and 5.4% on an organic basis. The company’s organic revenue results reflect broad-based growth across the company, with mid-single digit or higher organic revenue growth in all four segments. The organic revenue growth comparison excludes:
$57 million of current year revenue and $114 million of prior year revenue reported as Other, stemming from business separations and product line exits;
$72 million of unfavorable impact from foreign currency translation on the remaining segments; and
$265 million of prior year revenue from a one-time intellectual property (IP) agreement, which was reported in the Structural Heart & Aortic division in the Cardiovascular Portfolio

As reported, Q4 GAAP net income and diluted EPS were $654 million and $0.49, respectively, decreases of 45% and 44%, respectively. As detailed in the financial schedules included at the end of this release, Q4 non-GAAP net income and non-GAAP
2


diluted EPS were $1.929 billion and $1.46, respectively, decreases of 8% and 7%, respectively. Included in Q4 non-GAAP diluted EPS was a 7 cent, or 4%, unfavorable impact from foreign currency translation.

FY24 Financial Results
Medtronic reported FY24 worldwide revenue of $32.364 billion, an increase of 3.6% as reported and 5.2% on an organic basis. The FY24 organic revenue growth comparison excludes:
$111 million of current year revenue and $358 million of prior year revenue reported as Other, stemming from business separations and product line exits;
$43 million of favorable impact from foreign currency translation on the remaining segments; and
$265 million of prior year revenue from a one-time IP agreement.

FY24 GAAP net income and diluted earnings per share (EPS) were $3.676 billion and $2.76, respectively, both representing decreases of 2%. As detailed in the financial schedules included at the end of this release, fiscal year 2024 non-GAAP net income and non-GAAP diluted EPS were $6.918 billion and $5.20, respectively, both representing decreases of 2%. Included in FY24 non-GAAP diluted EPS was a 33 cent unfavorable impact from foreign currency translation. FY24 non-GAAP diluted EPS on a constant currency basis increased 5%.

FY24 cash from operations of $6.787 billion increased 12%. FY24 free cash flow of $5.200 billion increased 14%, representing free cash flow conversion from non-GAAP net earnings of 75%. Growth was driven by improvements in working capital.

“We delivered a strong finish to the fiscal year, with broad strength across our businesses and each of our four segments posting mid-single digit or higher organic revenue growth,” said Geoff Martha, Medtronic chairman and chief executive officer. “Our momentum is building into the new fiscal year. We’re beginning new product cycles in some of MedTech’s most attractive markets, which is further enhanced as we apply AI
3


across our portfolio. We are very optimistic about what we can achieve in fiscal ’25 and beyond.”

Cardiovascular Portfolio
The Cardiovascular Portfolio includes the Cardiac Rhythm & Heart Failure (CRHF), Structural Heart & Aortic (SHA), and Coronary & Peripheral Vascular (CPV) divisions. FY24 revenue of $11.831 billion increased 2.7% as reported and 5.0% organic, with a high-single digit increase in SHA, mid-single digit increase in CPV, and a low-single digit increase in CRHF, all on an organic basis. Q4 revenue of $3.130 billion decreased 5.2% as reported and increased 4.0% organic, with mid-single digit organic increases in SHA and CPV, and a low-single digit organic increase in CRHF.
CRHF Q4 results included low-single digit growth in Cardiac Rhythm Management, driven by high-single digit growth in Cardiac Pacing Therapies, including low-20s growth in Micra™ transcatheter pacing systems; Cardiac Ablation Solutions grew mid-single digits, with declines in cryoablation more than offset by strong growth in pulsed field ablation (PFA)
SHA Q4 results driven by high-single digit growth in Structural Heart and Cardiac Surgery; Structural Heart had double digit growth in Western Europe and Japan on the continued adoption of the Evolut™ FX transcatheter aortic valve replacement (TAVR) system
CPV in Q4 delivered mid-single digit Coronary growth with strength in guide catheters and balloons; Peripheral Vascular Health also grew mid-single digits, with mid-teens growth in drug-coated balloons and vascular embolization products
Received U.S. FDA approval for Evolut™ FX+ TAVR system in March, with early commercial experience this spring 2024 and full product launch in summer 2024; Launched Avalus Ultra™ surgical aortic tissue value in the U.S.; Symplicity Spyral™ renal denervation system received National Medical Products Administration (NMPA) approval in China and license from Health Canada
One-year results from SMART trial simultaneously presented at American College of Cardiology and published in The New England Journal of Medicine in
4


April, demonstrating Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annuli, which is primarily women
First-in-human data studying the Sphere-360™ PFA catheter presented at European Heart Rhythm Association annual meeting in April; one-year results from SPHERE-PER AF pivotal study of the Sphere-9™ pulsed field (PF) and radiofrequency (RF) ablation, and high density (HD) mapping catheter with the Affera cardiac mapping and navigation platform presented at Heart Rhythm last week, system has been submitted to U.S. FDA seeking approval

Neuroscience Portfolio
The Neuroscience Portfolio includes the Cranial & Spinal Technologies (CST), Specialty Therapies, and Neuromodulation divisions. FY24 revenue of $9.406 billion increased 5.0% as reported and 5.2% organic, with a high-single digit increase in CST, mid-single digit increase in Specialty Therapies, and a low-single digit increase in Neuromodulation, all on an organic basis. Q4 revenue of $2.545 billion increased 5.6% as reported and 6.5% organic, with a high-single digit increase in CST, a mid-single digit increase in Neuromodulation, and low-single digit increase in Specialty Therapies, all on an organic basis.
CST Q4 performance driven by continued adoption of the AiBLE™ ecosystem, with mid-teens growth in Neurosurgery on strong capital equipment sales, high-single digit growth in Biologics, and mid-single digit growth in Core Spine
Specialty Therapies Q4 results driven by high-single digit growth in ENT, with strength in power capital and disposables and localized drug delivery sinus implants; Neurovascular declined low-single digits, as declines in China due to volume-based procurement tenders offset strength in flow diversion products; Pelvic Health increased mid-single digits on continued adoption of the InterStim X™ system
Neuromodulation in Q4 delivered low-double digit growth in Brain Modulation on the launch of the Percept™ RC neurostimulator with BrainSense™ technology; Pain Therapies grew mid-single digits, including low-double digit growth in Targeted Drug Delivery and low-single digit growth in Pain Stim
5


Received U.S. FDA approval for Inceptiv™ closed-loop spinal cord stimulator on last day of Q4; received U.S. FDA clearance for OsteoCool™ 2.0 bone tumor ablation system in Q4, with broad market launch planned later this calendar year

Medical Surgical Portfolio
The Medical Surgical Portfolio includes the Surgical & Endoscopy (SE) and the Acute Care & Monitoring (ACM) divisions. FY24 revenue of $8.417 billion increased 5.4% as reported and 4.7% organic, with a mid-single digit increase in SE and low-single digit increase in ACM, both on an organic basis. Q4 revenue of $2.198 billion increased 3.5% as reported and 4.5% organic, with mid-single digit organic growth in SE and low-single digit organic growth in ACM.
SE Q4 results included high-single digit growth in General Surgical Technologies, with strength in wound management and hernia products, low-single digit growth in Advanced Surgical Technologies, and high-single digit growth in Endoscopy on strength of capital sales
ACM Q4 performance driven by mid-single digit growth in Blood Oxygen Management on strong sales of Nellcor™ pulse oximetry products, and mid-single digit growth in Airways, driven by strong McGRATH™ MAC video laryngoscope demand
Launched Touch Surgery™ Live Stream and 14 new AI-driven algorithms on the Touch Surgery™ Performance Insights platform for laparoscopic and robotic-assisted procedures; received U.S. FDA clearance for the BIS™ Advance anesthesia monitor; started enrollment in two new U.S. indication studies for the Hugo™ robotic-assisted surgery system: Hernia and Gynecology

Diabetes
Diabetes FY24 revenue of $2.488 billion increased 10.0% as reported and 8.6% organic. Q4 revenue of $660 million increased 10.9% as reported and 11.1% organic.
U.S. Q4 revenue grew low-double digits on the continued launch of the MiniMed™ 780G system; high-forties growth in U.S. insulin pump sales with strong growth in sales to new patients
6


Non-U.S. Developed Markets grew high-single digits on continued MiniMed™ 780G system adoption and increased CGM attachment rates
Submitted Simplera Sync™ CGM to U.S. FDA in Q4 seeking approval for use with the MiniMed™ 780G system

Guidance
The company today issued its fiscal year 2025 (FY25) revenue growth and EPS guidance.

The company is guiding to FY25 organic revenue growth in the range of 4% to 5%. The organic revenue growth guidance excludes the impact of foreign currency exchange and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY25 revenue growth on a reported basis would be in the range of 2.4% to 3.7%.

The company is guiding to FY25 diluted non-GAAP EPS in the range of $5.40 to $5.50, including an estimated 5% unfavorable impact from foreign currency exchange based on recent rates. This would represent FY25 diluted non-GAAP EPS growth in the range of 4 to 6%.

Dividend Increase
The company today announced that effective May 22, 2024, the Medtronic board of directors approved an increase in Medtronic’s cash dividend for the first quarter of fiscal year 2025, raising the quarterly amount to $0.70 per ordinary share. This would translate into an annual amount of $2.80 per ordinary share. Medtronic has a long history of dividend growth, and the company is a constituent of the S&P 500 Dividend Aristocrats index. Today's announcement marks the 47th consecutive year of an increase in the dividend payment. Including today's increase, Medtronic's dividend per share has grown by 30% over the past 5 years, 130% over the past 10 years, and has grown at a 16% compounded annual growth rate over the past 47 years.

7


Medtronic has a strong track record of returning capital to its shareholders, including $5.5 billion in fiscal year 2024. The company remains committed to returning a minimum of 50% of its free cash flow to shareholders, primarily through dividends, and to a lesser extent, share repurchases. The dividend is payable on July 12, 2024, to shareholders of record at the close of business on June 28, 2024.

“We delivered on our commitments in the fourth quarter and the fiscal year, driving durable revenue growth, improved earnings power, and strong free cash flow,” said Karen Parkhill, Medtronic EVP & chief financial officer. “Our fiscal 2025 guidance, along with our dividend increase and recent share repurchase, reflects our confidence in our continued trajectory.”

Video Webcast Information
Medtronic will host a video webcast today, May 23, at 8:00 a.m. EDT (7:00 a.m. CDT) to provide information about its businesses for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Events icon at investorrelations.medtronic.com, and this earnings release will be archived at news.medtronic.com. Within 24 hours of the webcast, a replay of the webcast and transcript of the company’s prepared remarks will be available by clicking on the Events icon at investorrelations.medtronic.com.

Medtronic plans to report its FY25 first, second, third, and fourth quarter results on Tuesday, August 20, 2024, November 19, 2024, February 18, 2025, and Thursday, May 22, 2025, respectively. Confirmation and additional details will be provided closer to the specific event.

Financial Schedules and Earnings Presentation
The fourth quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Investor Events link at investorrelations.medtronic.com.

About Medtronic
8


Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow on X and LinkedIn.

FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, general economic conditions, and other risks and uncertainties described in the company’s periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “looking ahead,” “may,” “plan,” “possible,” “potential,” “project,” “should,” “going to,” “will,” and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.

NON-GAAP FINANCIAL MEASURES
This press release contains financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered “non-GAAP” financial measures under
9


applicable SEC rules and regulations. References to quarterly or annual figures increasing, decreasing or remaining flat are in comparison to fiscal year 2023.

Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company’s underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management’s review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company’s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.

Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions or divestitures. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.

-end-
10



11


MEDTRONIC PLC
WORLD WIDE REVENUE(1)
(Unaudited)
FOURTH QUARTERFISCAL YEAR
REPORTEDORGANICREPORTEDORGANIC
(in millions)FY24FY23Growth
Currency Impact(3)
Adjusted FY24(4)
Adjusted FY23(5)
Adjusted GrowthFY24FY23Growth
Currency Impact(3)
Adjusted FY24(4)
Adjusted FY23(5)
Adjusted Growth
Cardiovascular$3,130 $3,302 (5.2)%$(28)$3,158 $3,037 4.0 %$11,831 $11,522 2.7 %$12 $11,819 $11,257 5.0 %
Cardiac Rhythm & Heart Failure1,587 1,567 1.3 (15)1,602 1,567 2.2 5,995 5,783 3.7 11 5,984 5,783 3.5 
Structural Heart & Aortic883 1,105 (20.1)(6)889 840 5.8 3,358 3,363 (0.1)11 3,347 3,098 8.0 
Coronary & Peripheral Vascular660 631 4.6 (7)667 631 5.7 2,478 2,375 4.3 (10)2,488 2,375 4.8 
Neuroscience
2,545 2,410 5.6 (21)2,566 2,410 6.5 9,406 8,959 5.0 (16)9,422 8,959 5.2 
Cranial & Spinal Technologies1,291 1,198 7.8 (11)1,302 1,198 8.7 4,756 4,451 6.9 (11)4,767 4,451 7.1 
Specialty Therapies778 763 2.0 (9)787 763 3.1 2,905 2,815 3.2 (12)2,917 2,815 3.6 
Neuromodulation475 449 5.8 (1)476 449 6.0 1,746 1,693 3.1 1,739 1,693 2.7 
Medical Surgical2,198 2,124 3.5 (22)2,220 2,124 4.5 8,417 7,989 5.4 16 8,512 8,127 4.7 
Surgical & Endoscopy1,705 1,638 4.1 (15)1,720 1,638 5.0 6,508 6,152 5.8 20 6,488 6,152 5.5 
Acute Care & Monitoring492 486 1.2 (6)498 486 2.5 1,908 1,837 3.9 (4)2,024 1,975 2.5 
Diabetes660 595 10.9 (1)661 595 11.1 2,488 2,262 10.0 31 2,457 2,262 8.6 
Other (2)
57 114 (50.0)(3)   221 495 (55.4)(12)   
TOTAL$8,589 $8,544 0.5 %$(75)$8,604 $8,165 5.4 %$32,364 $31,227 3.6 %$31 $32,210 $30,604 5.2 %

(1) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.
(2) Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions (RCS) business.
(3) The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.
(4) The three and twelve months ended April 26, 2024 excludes $57 million and $111 million, respectively, of inorganic revenue related to the activity noted in (2) and $72 million of unfavorable currency impact and $43 million of favorable currency impact on the remaining segments, respectively. The fiscal year organic revenue calculation reclassifies the first nine months of ventilator product line revenue of $110 million from the Other line to the Acute Care and Monitoring division of the Medical Surgical Portfolio.
(5) The three and twelve months ended April 28, 2023 excludes $379 million and $623 million, respectively, of inorganic revenue related to the following:
$265 million related to the one-time payment received as a result of the Intellectual Property Agreement entered into with Edwards Lifesciences in April 2023, which is included in the reported results of the Structural Heart & Aortic division of the Cardiovascular portfolio, and
$114 million and $358 million, respectively, of inorganic revenue related to the activity noted in (2). The fiscal year organic revenue calculation reclassifies the first nine months of ventilator product line revenue of $138 million from the Other line to the Acute Care and Monitoring division of the Medical Surgical Portfolio.
12


MEDTRONIC PLC
U.S.(1)(2) REVENUE
(Unaudited)
FOURTH QUARTERFISCAL YEAR
REPORTEDORGANICREPORTEDORGANIC
(in millions)FY24FY23
Growth
Adjusted FY24(4)
Adjusted FY23(5)
GrowthFY24FY23Growth
Adjusted FY24(4)
Adjusted FY23(5)
Growth
Cardiovascular$1,448 $1,737 (16.6)%$1,448 $1,472 (1.6)%$5,597 $5,796 (3.4)%$5,597 $5,531 1.2 %
Cardiac Rhythm & Heart Failure791 819 (3.4)791 819 (3.4)3,037 3,052 (0.5)3,037 3,052 (0.5)
Structural Heart & Aortic366 625 (41.4)366 360 1.7 1,453 1,622 (10.4)1,453 1,357 7.1 
Coronary & Peripheral Vascular291 293 (0.7)291 293 (0.7)1,107 1,122 (1.3)1,107 1,122 (1.3)
Neuroscience
1,692 1,581 7.0 1,692 1,581 7.0 6,305 6,018 4.8 6,305 6,018 4.8 
Cranial & Spinal Technologies936 855 9.5 936 855 9.5 3,495 3,259 7.2 3,495 3,259 7.2 
Specialty Therapies439 422 4.0 439 422 4.0 1,641 1,608 2.1 1,641 1,608 2.1 
Neuromodulation317 304 4.3 317 304 4.3 1,169 1,151 1.6 1,169 1,151 1.6 
Medical Surgical954 919 3.8 954 919 3.8 3,717 3,549 4.7 3,759 3,604 4.3 
Surgical & Endoscopy679 653 4.0 679 653 4.0 2,650 2,541 4.3 2,650 2,541 4.3 
Acute Care & Monitoring275 266 3.4 275 266 3.4 1,067 1,008 5.9 1,109 1,063 4.3 
Diabetes223 199 12.1 223 199 12.1 852 849 0.4 852 849 0.4 
Other (3)
26 39 (33.3)   91 160 (43.1)   
TOTAL$4,343 $4,476 (3.0)%$4,317 $4,171 3.5 %$16,562 $16,373 1.2 %$16,514 $16,003 3.2 %

(1) U.S. includes the United States and U.S. territories.
(2) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.
(3) Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions (RCS) business.
(4) The three and twelve months ended April 26, 2024 excludes $26 million and $48 million, respectively, of inorganic revenue related to the activity noted in (3). The fiscal year organic revenue calculation reclassifies the first nine months of ventilator product line revenue of $42 million from the Other line to the Acute Care and Monitoring division of the Medical Surgical Portfolio.
(5) The three and twelve months ended April 28, 2023 excludes $304 million and $370 million, respectively, of inorganic revenue related to the following:
$265 million related to the one-time payment received as a result of the Intellectual Property Agreement entered into with Edwards Lifesciences in April 2023, which is included in the reported results of the Structural Heart & Aortic division of the Cardiovascular portfolio, and
$39 million and $105 million, respectively, of inorganic revenue related to the activity noted in (3). The fiscal year organic revenue calculation reclassifies the first nine months of ventilator product line revenue of $55 million from the Other line to the Acute Care and Monitoring division of the Medical Surgical Portfolio.
13


MEDTRONIC PLC
WORLD WIDE REVENUE: GEOGRAPHIC (1)(2)
(Unaudited)
FOURTH QUARTERFISCAL YEAR
REPORTEDORGANICREPORTEDORGANIC
(in millions)FY24FY23Growth
Currency Impact(4)
Adjusted FY24(5)
Adjusted FY23(6)
Growth FY24FY23Growth
Currency Impact(4)
Adjusted FY24(5)
Adjusted FY23(6)
Growth
U.S.$1,448 $1,737 (16.6)%$— $1,448 $1,472 (1.6)%$5,597 $5,796 (3.4)%$— $5,597 $5,531 1.2 %
Non-U.S. Developed1,039 1,011 2.8 (13)1,052 1,011 4.1 3,857 3,564 8.2 62 3,795 3,564 6.5 
Emerging Markets643 554 16.1 (15)658 554 18.8 2,377 2,161 10.0 (49)2,426 2,161 12.3 
Cardiovascular3,130 3,302 (5.2)(28)3,158 3,037 4.0 11,831 11,522 2.7 12 11,819 11,257 5.0 
U.S.1,692 1,581 7.0 — 1,692 1,581 7.0 6,305 6,018 4.8 — 6,305 6,018 4.8 
Non-U.S. Developed482 469 2.8 (11)493 469 5.1 1,739 1,658 4.9 1,730 1,658 4.3 
Emerging Markets371 360 3.1 (10)381 360 5.8 1,362 1,283 6.2 (25)1,387 1,283 8.1 
Neuroscience2,545 2,410 5.6 (21)2,566 2,410 6.5 9,406 8,959 5.0 (16)9,422 8,959 5.2 
U.S.954 919 3.8 — 954 919 3.8 3,717 3,549 4.7 — 3,759 3,604 4.3 
Non-U.S. Developed805 799 0.8 (17)822 799 2.9 3,049 2,917 4.5 20 3,055 2,944 3.8 
Emerging Markets439 405 8.4 (5)444 405 9.6 1,650 1,522 8.4 (4)1,697 1,579 7.5 
Medical Surgical2,198 2,124 3.5 (22)2,220 2,124 4.5 8,417 7,989 5.4 16 8,512 8,127 4.7 
U.S.223 199 12.1 — 223 199 12.1 852 849 0.4 — 852 849 0.4 
Non-U.S. Developed337 314 7.3 336 314 7.0 1,284 1,106 16.1 37 1,247 1,106 12.7 
Emerging Markets99 82 20.7 (2)101 82 23.2 352 307 14.7 (6)358 307 16.6 
Diabetes660 595 10.9 (1)661 595 11.1 2,488 2,262 10.0 31 2,457 2,262 8.6 
U.S.26 39 (33.3)— — — — 91 160 (43.1)— — — — 
Non-U.S. Developed11 35 (68.6)(2)— — — 50 163 (69.3)(6)— — — 
Emerging Markets21 39 (46.2)(1)— — — 81 172 (52.9)(5)— — — 
Other (3)
57 114 (50.0)(3)   221 495 (55.4)(12)   
U.S.4,343 4,476 (3.0)— 4,317 4,171 3.5 16,562 16,373 1.2 — 16,514 16,003 3.2 
Non-U.S. Developed2,674 2,629 1.7 (42)2,702 2,593 4.2 9,979 9,408 6.1 121 9,828 9,272 6.0 
Emerging Markets1,572 1,440 9.2 (33)1,584 1,401 13.1 5,823 5,446 6.9 (89)5,869 5,330 10.1 
TOTAL$8,589 $8,544 0.5 %$(75)$8,604 $8,165 5.4 %$32,364 $31,227 3.6 %$31 $32,210 $30,604 5.2 %
(1) U.S. includes the United States and U.S. territories. Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries of Western Europe. Emerging Markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as previously defined.
(2) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.
(3) Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions (RCS) business.
(4) The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.
(5) The three and twelve months ended April 26, 2024 excludes $57 million and $111 million, respectively, of inorganic revenue related to the activity noted in (3) and $72 million of unfavorable currency impact and $43 million of favorable currency impact on the remaining segments, respectively. The fiscal year organic revenue calculation reclassifies the first nine months of ventilator product line revenue of $110 million from the Other line to the Acute Care and Monitoring division of the Medical Surgical Portfolio.
(6) The three and twelve months ended April 28, 2023 excludes $379 million and $623 million, respectively, of inorganic revenue related to the following:
$265 million related to the one-time payment received as a result of the Intellectual Property Agreement entered into with Edwards Lifesciences in April 2023, which is included in the reported results of the Structural Heart & Aortic division of the Cardiovascular portfolio, and
$114 million and $358 million, respectively, of inorganic revenue related to the activity noted in (3). The fiscal year organic revenue calculation reclassifies the first nine months of ventilator product line revenue of $138 million from the Other line to the Acute Care and Monitoring division of the Medical Surgical Portfolio.
14


MEDTRONIC PLC
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited) 
 Three months endedFiscal year ended
(in millions, except per share data)April 26, 2024April 28, 2023April 26, 2024April 28, 2023
Net sales$8,589 $8,544 $32,364 $31,227 
Costs and expenses:
Cost of products sold, excluding amortization of intangible assets3,044 2,980 11,216 10,719 
Research and development expense675 640 2,735 2,696 
Selling, general, and administrative expense2,765 2,616 10,736 10,415 
Amortization of intangible assets419 423 1,693 1,698 
Restructuring charges, net112 294 226 375 
Certain litigation charges, net44 (30)149 (30)
Other operating expense (income), net477 56 464 (131)
Operating profit1,053 1,565 5,144 5,485 
Other non-operating income, net(4)(173)(412)(515)
Interest expense, net202 187 719 636 
Income before income taxes856 1,551 4,837 5,364 
Income tax provision196 362 1,133 1,580 
Net income659 1,188 3,705 3,784 
Net income attributable to noncontrolling interests(5)(9)(28)(26)
Net income attributable to Medtronic$654 $1,179 $3,676 $3,758 
Basic earnings per share$0.49 $0.89 $2.77 $2.83 
Diluted earnings per share$0.49 $0.88 $2.76 $2.82 
Basic weighted average shares outstanding1,322.3 1,330.4 1,327.7 1,329.8 
Diluted weighted average shares outstanding1,325.4 1,332.8 1,330.2 1,332.8 
The data in the schedule above has been intentionally rounded to the nearest million, and therefore, the quarterly amounts may not sum to the fiscal year-to-date amounts.
15


MEDTRONIC PLC
GAAP TO NON-GAAP RECONCILIATIONS(1)
(Unaudited) 
 Three months ended April 26, 2024
(in millions, except per share data)Net SalesCost of Products SoldGross Margin PercentOperating ProfitOperating Profit PercentIncome Before Income TaxesNet Income attributable to MedtronicDiluted EPSEffective Tax Rate
GAAP$8,589 $3,044 64.6 %$1,053 12.3 %$856 $654 $0.49 22.9 %
Non-GAAP Adjustments:
Amortization of intangible assets— — — 419 4.9 419 357 0.27 15.0 
Restructuring and associated costs (2)— (13)0.2 152 1.8 152 125 0.09 17.8 
Acquisition and divestiture-related items (3)— (76)0.9 611 7.1 611 515 0.39 15.9 
Certain litigation charges, net— — — 44 0.5 44 37 0.03 15.9 
(Gain)/loss on minority investments (4)— — — — — 195 197 0.15 (1.0)
Medical device regulations (5)— (21)0.2 31 0.4 31 27 0.02 12.9 
Certain tax adjustments, net— — — — — — 17 0.01 — 
Non-GAAP$8,589 $2,934 65.8 %$2,311 26.9 %$2,309 $1,929 $1.46 16.2 %
Currency impact75 18 0.1 101 0.9 0.07 
Currency Adjusted$8,664 $2,952 65.9 %$2,412 27.8 %$1.53 
 Three months ended April 28, 2023
(in millions, except per share data)Net SalesCost of Products SoldGross Margin PercentOperating ProfitOperating Profit PercentIncome Before Income TaxesNet Income attributable to MedtronicDiluted EPSEffective Tax Rate
GAAP$8,544 $2,980 65.1 %$1,565 18.3 %$1,551 $1,179 $0.88 23.3 %
Non-GAAP Adjustments:
Amortization of intangible assets— — — 423 5.0 423 361 0.27 14.7 
Restructuring and associated costs (2)— (30)0.4 372 4.4 372 288 0.22 22.6 
Acquisition and divestiture-related items (6)— (7)0.1 139 1.6 139 131 0.10 5.8 
Certain litigation charges, net (7)— — — (30)(0.4)(30)(22)(0.02)26.7 
(Gain)/loss on minority investments (4)— — — — — (10)(7)(0.01)(20.0)
Medical device regulations (5)— (25)0.3 44 0.5 44 34 0.03 22.7 
Certain tax adjustments, net (8)— — — — — — 127 0.10 — 
Non-GAAP$8,544 $2,917 65.9 %$2,512 29.4 %$2,488 $2,091 $1.57 15.8 %
See description of non-GAAP financial measures contained in the press release dated May 23, 2024.
(1)The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.
(2)Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program, consulting expenses, and asset write-offs.
(3)The charges predominantly include $439 million of charges related to the February 20, 2024 decision to exit the Company's ventilator product line, which primarily includes long-lived intangible asset impairments and inventory write-downs. In addition, other charges primarily consist of changes in fair value of contingent consideration.
(4)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.
(5)The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific period.
(6)The charges primarily include changes in the carrying value of the disposal group and other associated costs as a result of the April 2023 sale of half of the Company's Renal Care Solutions (RCS) business, changes in fair value of contingent consideration, business combination costs, and associated costs related to the previously contemplated separation of the PMRI businesses.
(7)Certain litigation includes $35 million related to the one-time payment received as a result of the Intellectual Property Agreement entered into with Edwards Lifesciences in April 2023.
(8)The charge primarily relates to the reduction of deferred tax assets due to the disallowance of certain interest deductions and the change in the reporting currency for certain carryover attributes, and the impact from the sale of half of the Company’s RCS business.
16


MEDTRONIC PLC
GAAP TO NON-GAAP RECONCILIATIONS(1)
(Unaudited) 
 Fiscal year ended April 26, 2024
(in millions, except per share data)Net SalesCost of Products SoldGross Margin PercentOperating ProfitOperating Profit PercentIncome Before Income TaxesNet Income attributable to MedtronicDiluted EPSEffective Tax Rate
GAAP$32,364 $11,216 65.3 %$5,144 15.9 %$4,837 $3,676 $2.76 23.4 %
Non-GAAP Adjustments:
Amortization of intangible assets— — — 1,693 5.2 1,693 1,435 1.08 15.2 
Restructuring and associated costs (2)— (55)0.2 389 1.2 389 323 0.24 17.0 
Acquisition and divestiture-related items (3)— (100)0.3 777 2.4 777 664 0.50 14.5 
Certain litigation charges— — — 149 0.5 149 118 0.09 20.8 
(Gain)/loss on minority investments (4)— — — — — 308 305 0.23 0.6 
Medical device regulations (5)— (81)0.3 119 0.4 119 97 0.07 18.5 
Certain tax adjustments, net (6)— — — — — — 299 0.22 — 
Non-GAAP$32,364 $10,980 66.1 %$8,272 25.6 %$8,273 $6,918 $5.20 16.0 %
Currency impact(31)(114)0.3 507 1.6 0.33 
Currency Adjusted$32,333 $10,866 66.4 %$8,779 27.2 %$5.53 
 Fiscal year ended April 28, 2023
(in millions, except per share data)Net SalesCost of Products SoldGross Margin PercentOperating ProfitOperating Profit PercentIncome Before Income TaxesNet Income attributable to MedtronicDiluted EPSEffective Tax Rate
GAAP$31,227 $10,719 65.7 %$5,485 17.6 %$5,364 $3,758 $2.82 29.5 %
Non-GAAP Adjustments:
Amortization of intangible assets— — — 1,698 5.4 1,698 1,443 1.08 15.0 
Restructuring and associated costs (2)— (97)0.3 647 2.1 647 507 0.38 21.5 
Acquisition and divestiture-related items (7)— (66)0.2 345 1.1 345 316 0.24 8.4 
Certain litigation charges, net (8)— — — (30)(0.1)(30)(23)(0.02)26.7 
(Gain)/loss on minority investments (4)— — — — — (33)(29)(0.02)(6.1)
Medical device regulations (5)— (88)0.3 150 0.5 150 120 0.09 20.0 
Debt redemption premium and other charges (9)— — — — — 53 42 0.03 20.8 
Certain tax adjustments, net (10)— — — — — — 910 0.68 — 
Non-GAAP$31,227 $10,469 66.5 %$8,295 26.6 %$8,194 $7,045 $5.29 13.8 %
See description of non-GAAP financial measures contained in the press release dated May 23, 2024.
(1)The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.
(2)Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program, consulting expenses, and asset write-offs.
(3)The charges predominantly include $439 million of charges related to the February 20, 2024 decision to exit the Company's ventilator product line, which primarily includes long-lived intangible asset impairments and inventory write-downs. In addition, other charges primarily consist of changes in fair value of contingent consideration and associated costs related to the previously contemplated separation of the PMRI businesses.
(4)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.
(5)The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period.
(6)The net charge primarily relates to an income tax reserve adjustment associated with the June 2023, Israeli Central-Lod District Court decision and the establishment of a valuation allowance against certain net operating losses which were partially offset by a benefit from the change in a Swiss Cantonal tax rate associated with previously established deferred tax assets from intercompany intellectual property transactions and the step up in tax basis for Swiss Cantonal purposes.
(7)The charges predominantly include non-cash pre-tax impairments, primarily related to goodwill, changes in the carrying value of the disposal group, and other associated costs, as a result of the April 2023 sale of half of the Company's Renal Care Solutions (RCS) business; business combination costs, and associated costs related to the previously contemplated separation of the PMRI businesses.
(8)Certain litigation includes $35 million income related to the one-time payment received as a result of the Intellectual Property Agreement entered into with Edwards Lifesciences in April 2023.
(9)The charges relate to the early redemption of approximately $2.3 billion of debt and were recorded within interest expense, net within the consolidated statements of income.
(10)The charge primarily relates to a $764 million reserve adjustment that was a direct result of the U.S. Tax Court opinion, issued in August 2022, on the previously disclosed litigation regarding the allocation of income between Medtronic, Inc. and its wholly owned subsidiary operating in Puerto Rico. Additional charges relate to the reduction of deferred tax assets due to the disallowance of certain interest deductions and the change in the reporting currency for certain carryover attributes, and the amortization on previously established deferred tax assets from intercompany intellectual property transactions.
17


MEDTRONIC PLC
GAAP TO NON-GAAP RECONCILIATIONS(1)
(Unaudited) 
 Three months ended April 26, 2024
(in millions)Net SalesSG&A ExpenseSG&A Expense as a % of Net SalesR&D ExpenseR&D Expense as a % of Net SalesOther Operating (Income) Expense, netOther Operating (Inc.)/Exp., net as a % of Net SalesOther Non-Operating Income, net
GAAP$8,589 $2,765 32.2 %$675 7.9 %$477 5.6 %$(4)
Non-GAAP Adjustments:
Restructuring and associated costs (2)— (28)(0.3)— — — — — 
Acquisition and divestiture-related items (3)— (6)(0.1)— — (530)(6.2)— 
Medical device regulations (4)— (1)— (9)(0.1)— — — 
(Gain)/loss on minority investments (5)— — — — — — — (195)
Non-GAAP$8,589 $2,731 31.8 %$666 7.8 %$(52)(0.6)%$(200)

 Fiscal year ended April 26, 2024
(in millions)Net SalesSG&A ExpenseSG&A Expense as a % of Net SalesR&D ExpenseR&D Expense as a % of Net SalesOther Operating (Income) Expense, netOther Operating (Inc.)/Exp., net as a % of Net SalesOther Non-Operating Income, net
GAAP$32,364 $10,736 33.2 %$2,735 8.5 %$464 1.4 %$(412)
Non-GAAP Adjustments:
Restructuring and associated costs (2)— (108)(0.3)— — — — — 
Acquisition and divestiture-related items (3)— (71)(0.2)— — (606)(1.9)— 
Medical device regulations (4)— (2)— (36)(0.1)— — — 
(Gain)/loss on minority investments (5)— — — — — — — (308)
Non-GAAP$32,364 $10,555 32.6 %$2,698 8.3 %$(141)(0.4)%$(720)
See description of non-GAAP financial measures contained in the press release dated May 23, 2024.
(1)The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.
(2)Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.
(3)The charges predominantly include $439 million of charges related to the February 20, 2024 decision to exit the Company's ventilator product line, which primarily includes long-lived intangible asset impairments. In addition, other charges primarily related to changes in fair of contingent consideration and associated costs related to the previously contemplated separation of the PMRI businesses.
(4)The charges represent estimated incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period.
(5)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.
18


MEDTRONIC PLC
GAAP TO NON-GAAP RECONCILIATIONS(1)
(Unaudited)
Fiscal Year
(in millions)202420232022
Net cash provided by operating activities$6,787 $6,039 $7,346 
Additions to property, plant, and equipment(1,587)(1,459)(1,368)
Free Cash Flow (2)
$5,200 $4,580 $5,978 
See description of non-GAAP financial measures contained in the press release dated May 23, 2024.
(1)The data in this schedule has been intentionally rounded to the nearest million, and therefore, may not sum.
(2)Free cash flow represents operating cash flows less property, plant, and equipment additions.
19


MEDTRONIC PLC
CONSOLIDATED BALANCE SHEETS
(Unaudited)
 
(in millions)April 26, 2024April 28, 2023
ASSETS
Current assets:
Cash and cash equivalents$1,284 $1,543 
Investments6,721 6,416 
Accounts receivable, less allowances and credit losses of $173 and $176, respectively
6,128 5,998 
Inventories, net5,217 5,293 
Other current assets2,584 2,425 
Total current assets21,935 21,675 
Property, plant, and equipment, net6,131 5,569 
Goodwill40,986 41,425 
Other intangible assets, net13,225 14,844 
Tax assets3,657 3,477 
Other assets4,047 3,959 
Total assets$89,981 $90,948 
LIABILITIES AND EQUITY
Current liabilities:
Current debt obligations$1,092 $20 
Accounts payable2,410 2,662 
Accrued compensation2,375 1,949 
Accrued income taxes1,330 840 
Other accrued expenses3,582 3,581 
Total current liabilities10,789 9,051 
Long-term debt23,932 24,344 
Accrued compensation and retirement benefits1,101 1,093 
Accrued income taxes1,859 2,360 
Deferred tax liabilities515 708 
Other liabilities1,365 1,727 
Total liabilities39,561 39,283 
Commitments and contingencies
Shareholders’ equity:
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,311,337,531 and 1,330,809,036 shares issued and outstanding, respectively
— — 
Additional paid-in capital23,129 24,590 
Retained earnings30,403 30,392 
Accumulated other comprehensive loss(3,318)(3,499)
Total shareholders’ equity50,214 51,483 
Noncontrolling interests206 182 
Total equity50,420 51,665 
Total liabilities and equity$89,981 $90,948 

The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.
20


MEDTRONIC PLC
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
 Fiscal Year
(in millions)202420232022
Operating Activities:   
Net income$3,705 $3,784 $5,062 
Adjustments to reconcile net income to net cash provided by operating activities:   
Depreciation and amortization2,647 2,697 2,707 
Provision for credit losses90 73 58 
Deferred income taxes(508)(226)(604)
Stock-based compensation393 355 359 
Loss on debt extinguishment— 53 — 
Asset impairments and inventory write-downs371 — 515 
Other, net573 270 138 
Change in operating assets and liabilities, net of acquisitions and divestitures:   
Accounts receivable, net(391)(576)(477)
Inventories, net(139)(939)(560)
Accounts payable and accrued liabilities391 696 213 
Other operating assets and liabilities(345)(148)(65)
Net cash provided by operating activities6,787 6,039 7,346 
Investing Activities:   
Acquisitions, net of cash acquired(211)(1,867)(91)
Additions to property, plant, and equipment(1,587)(1,459)(1,368)
Purchases of investments(7,748)(7,514)(9,882)
Sales and maturities of investments7,441 7,343 9,692 
Other investing activities, net(261)(10)
Net cash used in investing activities(2,366)(3,493)(1,659)
Financing Activities:   
Change in current debt obligations, net1,073 — — 
Proceeds from short-term borrowings (maturities greater than 90 days)— 2,284 — 
Repayments from short-term borrowings (maturities greater than 90 days)— (2,279)— 
Issuance of long-term debt— 5,409 — 
Payments on long-term debt— (6,012)(1)
Dividends to shareholders(3,666)(3,616)(3,383)
Issuance of ordinary shares284 308 429 
Repurchase of ordinary shares(2,138)(645)(2,544)
Other financing activities(3)(409)163 
Net cash used in financing activities(4,450)(4,960)(5,336)
Effect of exchange rate changes on cash and cash equivalents(230)243 (231)
Net change in cash and cash equivalents(259)(2,171)121 
Cash and cash equivalents at beginning of period1,543 3,714 3,593 
Cash and cash equivalents at end of period$1,284 $1,543 $3,714 
Supplemental Cash Flow Information   
Cash paid for:   
Income taxes$1,622 $1,548 $996 
Interest826 606 540 

The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.
21
EX-101.SCH 3 mdt-20240523.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 mdt-20240523_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 mdt-20240523_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, Country Entity Address, Country 0.000% Senior Notes due 2025 Senior Notes 2020 Due 2025 [Member] Senior Notes 2020 Due 2025 1.375% Senior Notes due 2040 Senior Notes 2020 Due 2040 [Member] Senior Notes 2020 Due 2040 1.500% Senior Notes due 2039 Senior Notes 2019 Due 2039, 1.50 Percent [Member] Senior Notes 2019 Due 2039, 1.50 Percent [Member] Entity Information [Line Items] Entity Information [Line Items] Document Period End Date Document Period End Date Ordinary shares, par value $0.0001 per share Common Stock [Member] Pre-commencement Tender Offer Pre-commencement Tender Offer Class of Stock [Domain] Class of Stock [Domain] Soliciting Material Soliciting Material 1.750% Senior Notes due 2049 Senior Notes 2019 Due 2049 [Member] Senior Notes 2019 Due 2049 [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Entity Central Index Key Entity Central Index Key 2.625% Senior Notes due 2025 Senior Notes Due 2025 [Member] Senior Notes Due 2025 1.625% Senior Notes due 2050 Senior Notes 2020 Due 2050 [Member] Senior Notes 2020 Due 2050 Entity Address, City or Town Entity Address, City or Town Country Region Country Region 0.375% Senior Notes due 2028 Senior Notes 2020 Due 2028 [Member] Senior Notes 2020 Due 2028 Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol 3.125% Senior Notes due 2031 Senior Notes Due 2031 [Member] Senior Notes Due 2031 Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code 0.250% Senior Notes due 2025 Senior Notes 2019 Due 2025 [Member] Senior Notes 2019 Due 2025 [Member] 1.000% Senior Notes due 2031 Senior Notes 2019 Due 2031, 1.00 Percent [Member] Senior Notes 2019 Due 2031, 1.00 Percent [Member] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover page. Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company 1.625% Senior Notes due 2031 Senior Notes 2019 Due 2031, 1.625 Percent [Member] Senior Notes 2019 Due 2031, 1.625 Percent [Member] 3.000% Senior Notes due 2028 Senior Notes Due 2028 [Member] Senior Notes Due 2028 3.375% Senior Notes due 2034 Senior Notes Due 2034 [Member] Senior Notes Due 2034 0.750% Senior Notes due 2032 Senior Notes 2020 Due 2032 [Member] Senior Notes 2020 Due 2032 Document Type Document Type 2.250% Senior Notes due 2039 Senior Notes 2019 Due 2039, 2.250 Percent [Member] Senior Notes 2019 Due 2039, 2.250 Percent [Member] Amendment Flag Amendment Flag Class of Stock [Axis] Class of Stock [Axis] Entity File Number Entity File Number Entities [Table] Entities [Table] Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name 1.125% Senior Notes due 2027 Senior Notes 2019 Due 2027 [Member] Senior Notes 2019 Due 2027 [Member] EX-101.PRE 6 mdt-20240523_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 image_0a.jpg IMAGE 0 begin 644 image_0a.jpg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htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
May 23, 2024
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date May 23, 2024
Entity Incorporation, State or Country Code L2
Entity File Number 1-36820
Entity Tax Identification Number 98-1183488
Entity Address, Address Line One 20 On Hatch, Lower Hatch Street
Entity Address, City or Town Dublin 2
Entity Address, Country IE
Country Region 353
City Area Code 1
Local Phone Number 438-1700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001613103
Entity Registrant Name Medtronic plc
Entity Address, Postal Zip Code D02 XH02
Amendment Flag false
Ordinary shares, par value $0.0001 per share  
Entity Information [Line Items]  
Title of 12(b) Security Ordinary shares, par value $0.0001 per share
Trading Symbol MDT
Security Exchange Name NYSE
0.250% Senior Notes due 2025  
Entity Information [Line Items]  
Title of 12(b) Security 0.250% Senior Notes due 2025
Trading Symbol MDT/25
Security Exchange Name NYSE
0.000% Senior Notes due 2025  
Entity Information [Line Items]  
Title of 12(b) Security 0.000% Senior Notes due 2025
Trading Symbol MDT/25A
Security Exchange Name NYSE
2.625% Senior Notes due 2025  
Entity Information [Line Items]  
Title of 12(b) Security 2.625% Senior Notes due 2025
Trading Symbol MDT/25B
Security Exchange Name NYSE
1.125% Senior Notes due 2027  
Entity Information [Line Items]  
Title of 12(b) Security 1.125% Senior Notes due 2027
Trading Symbol MDT/27
Security Exchange Name NYSE
0.375% Senior Notes due 2028  
Entity Information [Line Items]  
Title of 12(b) Security 0.375% Senior Notes due 2028
Trading Symbol MDT/28
Security Exchange Name NYSE
3.000% Senior Notes due 2028  
Entity Information [Line Items]  
Title of 12(b) Security 3.000% Senior Notes due 2028
Trading Symbol MDT/28A
Security Exchange Name NYSE
1.625% Senior Notes due 2031  
Entity Information [Line Items]  
Title of 12(b) Security 1.625% Senior Notes due 2031
Trading Symbol MDT/31
Security Exchange Name NYSE
1.000% Senior Notes due 2031  
Entity Information [Line Items]  
Title of 12(b) Security 1.000% Senior Notes due 2031
Trading Symbol MDT/31A
Security Exchange Name NYSE
3.125% Senior Notes due 2031  
Entity Information [Line Items]  
Title of 12(b) Security 3.125% Senior Notes due 2031
Trading Symbol MDT/31B
Security Exchange Name NYSE
0.750% Senior Notes due 2032  
Entity Information [Line Items]  
Title of 12(b) Security 0.750% Senior Notes due 2032
Trading Symbol MDT/32
Security Exchange Name NYSE
3.375% Senior Notes due 2034  
Entity Information [Line Items]  
Title of 12(b) Security 3.375% Senior Notes due 2034
Trading Symbol MDT/34
Security Exchange Name NYSE
2.250% Senior Notes due 2039  
Entity Information [Line Items]  
Title of 12(b) Security 2.250% Senior Notes due 2039
Trading Symbol MDT/39A
Security Exchange Name NYSE
1.500% Senior Notes due 2039  
Entity Information [Line Items]  
Title of 12(b) Security 1.500% Senior Notes due 2039
Trading Symbol MDT/39B
Security Exchange Name NYSE
1.375% Senior Notes due 2040  
Entity Information [Line Items]  
Title of 12(b) Security 1.375% Senior Notes due 2040
Trading Symbol MDT/40A
Security Exchange Name NYSE
1.750% Senior Notes due 2049  
Entity Information [Line Items]  
Title of 12(b) Security 1.750% Senior Notes due 2049
Trading Symbol MDT/49
Security Exchange Name NYSE
1.625% Senior Notes due 2050  
Entity Information [Line Items]  
Title of 12(b) Security 1.625% Senior Notes due 2050
Trading Symbol MDT/50
Security Exchange Name NYSE
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 18 23 1 false 17 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.medtronic.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressPostalZipCode, dei:EntityRegistrantName - mdt-20240523.htm 4 mdt-20240523.htm mdt-20240523.xsd mdt-20240523_def.xml mdt-20240523_lab.xml mdt-20240523_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mdt-20240523.htm": { "nsprefix": "mdt", "nsuri": "http://www.medtronic.com/20240523", "dts": { "inline": { "local": [ "mdt-20240523.htm" ] }, "schema": { "local": [ "mdt-20240523.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "mdt-20240523_def.xml" ] }, "labelLink": { "local": [ "mdt-20240523_lab.xml" ] }, "presentationLink": { "local": [ "mdt-20240523_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 16, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 18, "entityCount": 1, "segmentCount": 17, "elementCount": 45, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 71 }, "report": { "R1": { "role": "http://www.medtronic.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdt-20240523.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdt-20240523.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Ordinary shares, par value $0.0001 per share", "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Country Region", "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "mdt_SeniorNotes2019Due2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotes2019Due2025Member", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "0.250% Senior Notes due 2025", "label": "Senior Notes 2019 Due 2025 [Member]", "documentation": "Senior Notes 2019 Due 2025 [Member]" } } }, "auth_ref": [] }, "mdt_SeniorNotes2019Due2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotes2019Due2027Member", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "1.125% Senior Notes due 2027", "label": "Senior Notes 2019 Due 2027 [Member]", "documentation": "Senior Notes 2019 Due 2027 [Member]" } } }, "auth_ref": [] }, "mdt_SeniorNotes2019Due20311.00PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotes2019Due20311.00PercentMember", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "1.000% Senior Notes due 2031", "label": "Senior Notes 2019 Due 2031, 1.00 Percent [Member]", "documentation": "Senior Notes 2019 Due 2031, 1.00 Percent [Member]" } } }, "auth_ref": [] }, "mdt_SeniorNotes2019Due20311.625PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotes2019Due20311.625PercentMember", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "1.625% Senior Notes due 2031", "label": "Senior Notes 2019 Due 2031, 1.625 Percent [Member]", "documentation": "Senior Notes 2019 Due 2031, 1.625 Percent [Member]" } } }, "auth_ref": [] }, "mdt_SeniorNotes2019Due20391.50PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotes2019Due20391.50PercentMember", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "1.500% Senior Notes due 2039", "label": "Senior Notes 2019 Due 2039, 1.50 Percent [Member]", "documentation": "Senior Notes 2019 Due 2039, 1.50 Percent [Member]" } } }, "auth_ref": [] }, "mdt_SeniorNotes2019Due20392.250PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotes2019Due20392.250PercentMember", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "2.250% Senior Notes due 2039", "label": "Senior Notes 2019 Due 2039, 2.250 Percent [Member]", "documentation": "Senior Notes 2019 Due 2039, 2.250 Percent [Member]" } } }, "auth_ref": [] }, "mdt_SeniorNotes2019Due2049Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotes2019Due2049Member", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "1.750% Senior Notes due 2049", "label": "Senior Notes 2019 Due 2049 [Member]", "documentation": "Senior Notes 2019 Due 2049 [Member]" } } }, "auth_ref": [] }, "mdt_SeniorNotes2020Due2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotes2020Due2025Member", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "0.000% Senior Notes due 2025", "label": "Senior Notes 2020 Due 2025 [Member]", "documentation": "Senior Notes 2020 Due 2025" } } }, "auth_ref": [] }, "mdt_SeniorNotes2020Due2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotes2020Due2028Member", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "0.375% Senior Notes due 2028", "label": "Senior Notes 2020 Due 2028 [Member]", "documentation": "Senior Notes 2020 Due 2028" } } }, "auth_ref": [] }, "mdt_SeniorNotes2020Due2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotes2020Due2032Member", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "0.750% Senior Notes due 2032", "label": "Senior Notes 2020 Due 2032 [Member]", "documentation": "Senior Notes 2020 Due 2032" } } }, "auth_ref": [] }, "mdt_SeniorNotes2020Due2040Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotes2020Due2040Member", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "1.375% Senior Notes due 2040", "label": "Senior Notes 2020 Due 2040 [Member]", "documentation": "Senior Notes 2020 Due 2040" } } }, "auth_ref": [] }, "mdt_SeniorNotes2020Due2050Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotes2020Due2050Member", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "1.625% Senior Notes due 2050", "label": "Senior Notes 2020 Due 2050 [Member]", "documentation": "Senior Notes 2020 Due 2050" } } }, "auth_ref": [] }, "mdt_SeniorNotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotesDue2025Member", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "2.625% Senior Notes due 2025", "label": "Senior Notes Due 2025 [Member]", "documentation": "Senior Notes Due 2025" } } }, "auth_ref": [] }, "mdt_SeniorNotesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotesDue2028Member", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "3.000% Senior Notes due 2028", "label": "Senior Notes Due 2028 [Member]", "documentation": "Senior Notes Due 2028" } } }, "auth_ref": [] }, "mdt_SeniorNotesDue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotesDue2031Member", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "3.125% Senior Notes due 2031", "label": "Senior Notes Due 2031 [Member]", "documentation": "Senior Notes Due 2031" } } }, "auth_ref": [] }, "mdt_SeniorNotesDue2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20240523", "localname": "SeniorNotesDue2034Member", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "3.375% Senior Notes due 2034", "label": "Senior Notes Due 2034 [Member]", "documentation": "Senior Notes Due 2034" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.medtronic.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001613103-24-000058-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001613103-24-000058-xbrl.zip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

[1.5[ KZ)JMU]B''5':$26KSN(EW5);/"^;9@%-0;)$>8?':#J#>SX+ M$[@ER<;5J,"4)NN)!??4P2^HNR@,D#T=HLU:@!(NQ1 MQ..R-79%D?;*P;MC-%@.Q_.Z\H(4;]L'#:XOO'\"J2T@]M#O90]$JEE/Q>V" MV^5HO65JW"[RP/TU%<6Q%_%=\I]\'2/Q\''LUZ. N4??\Y\L2?EXOF\ A@OZ MRP'/1(0(]UY&Q)1'ZX01GZ:4\)"D$YZ0Q)LP/P.R3FA"1HR%T@P1YD$HP9Q( M:$1J9 2?9R1D(C(N)=,\N$X3)[,FGL1L',5,(U,Z)V$$"\VFO:WT*:9DF[V^ M,-#,HD1&O9S%+* BK.[\@?OII&"BQR\6W*"O7J$C #Y+M[_R" N/"0O+\?>" MF5LHGH4*/OI73)?[?_^!^Z.10WWFVKKCVR;\-AC[EN[:8]VCMD^'_W;,'Q8O M3>)5?.8=.QW%C/[WE(YAA6*#SY"D=ICP\?4;WYR3;RMHO,?B1B+JF*4JB M?O[P_O;;]9>K2_+UT^4NV['6V5Y>?[FY_G3U_N+VPWMRI5,LU&^26=,FPEE(N&J$,\N(D7WE3QWIRKVE_L2,B7:BX1VY M$!E*;VSX6,&VK0AU*IV;QV]2BN1$#(1CKF.J=K5JF.C3G?L&WB-G7@1H49LI*YIWQ=)(H(FIC/*XU6C'A[> MP\]1/"5O]L@4>4-MKA+1 F(Y][)9N!GP\I7R19QQ&(7L9 MU29_$HG0P>N9;$&LB3#(CMW&G-*^4-3SCQW(TJ^QU0M"M%.=5JOY_>$;(ZLO M)S2\8Z(:TZ, =7$UR^]CCVH@2H%.HC&AWI\9SZL?Y1_R^3U+4IYF,8:T8X V M4JQ)(>VFTX"T&\^#U8!$BIG'^+VHR-1%[?+$&AH8MZ$N/$X?PVH4AL?N]QL? M5M,$:7U5F/ 7*F/'K/:A(\-SQ#A41D>Q]5K@:>S.O6,SF5=5)DJ MZGEQQI[<^CNF8X.*C>9!M2%RA]AI2W&(3*-&/TC7]&WI;7O5>MLU+=RR'53S MU(7'L$MDB"$\1T]!JF?S[$D)5T1<;ZZ/^V77XE!OT;S;UA?/U?J#BN4GFM+4 MJMOPZE;9]!F$MS'P]C7+KGAG4Z^II=(NY,U'CK#()_LNR:XF 3#J "FF#,4Z M5CO]XE%Y1H L8:HMV[_/*I<8:+ QT-"<00DQB=;:XP-D M.QC4HC1 EEN/OZ-C5Y"O6>Q-: (#PM6#2[.'K"W0M8M'7^N7<;"A9GM\@!RC MGBI_"-!N5P]M,#!5O'VT3?&^H0'+HU6F-,UB:9S>A_1NKKK0UVP;*\ H#Y)E M8]U,Q4$::NZP;'-_^K"T_Q&G2T'Z,0HD0BD MGOJMB*1^)08Q2V2GBHU"^RU:=]LBF$Y,S7)+9'=7: S?%#6P==!:FCVT$-HV M0FMH;@7'B'HQAYN/-Z6/F(\\I*&WKYA#I0FP]PBZ714_I!A2[,TQA\VV'J_* MUWE9'#.8@.P)$8U@:G05B=@Q"[*AZ=B54760L(8XPH16Y$VMCX%V?D+&<30E MR22*T].4Q5,":GDW^*DDR&GI,1/@%47B7"WIALT&5';5!]6!R-%NO6)D$0>K,7NJ8ROYUH;!' MX3Z$.&H/J.0=N)R=IALEDCD0H*,':F!RY.&I_)Z+>H.A+U/MG&K0C1L=.>S++6+-2WW^#9+,J1[$MZ-UAC,#7#PHHD"@/DEFF8@? < M?_\X=CT%8SJF<>=9[.-E^LI^$B*;R'+ED^)0CSL:.+:.827JPF.X-:9?="&] M<"V#?6\"NR!&ZW)A;8_J7PNA'9;IFHO0-@=:1[.L\IX0]3+8 ME2Z2LIGV'\9CYLD>%NR[EZ>9QC1E)/]9!K_DS2U"/_]!% B_IT$'*Q:>F%8] M7;M1&]W)=8*5"E6'"'90HV-@%)'D+UP65H4"]BJTVZIXF&4*YZ!&V2!@-:-? MOC E0JL^M(99MFHT7A?V6(EFV[%":$I&[(Z'H;!.P75B!E\05>N%UUP%Q] < MU$)5!\G2^@9&62D/DC-$[\)!+PPORG(&?]\JQ0^KZ7C7>\^2$^D9ZUUI5^(0&Y %+ 4 M7C,*9P"(+JQ;CU78D6**R9<73%J&V3-5%S!7H1=-&4GI]_4XU3<;+95;[>XW MDDU+5/O286BN66.3R3TI.LASS>(YQVY^KC7R7)-X;CAT&^]U:I!ZD+*8)5VK MBCHPR_+8"S@W( 2I@1"Y.D*D.$2.K==<"_77E(X"!O_[_/[=;_#/XJL?C?6? M+$GY>%[0Z-UO(_%>,=^=7]L;:8<+RLH!SW@*W^:]3&M3T/IVPHA/4RHBB],) M3TCB39B?!8Q,:$)&C(GFNBD+A?&;!L&<2+HS7]3@2^'=D(EJ("F!N0;P$4V$ M'6CB2>Q2R@*;]GYP_<3R<% M>SQ^,8>$Q<4P=G\LEY4WC*3F>_#N*_#G\-TFGP;O_ M#U!+ P04 " #U-;=8V*ZC@B83 !YY@ $ &UD="TR,#(T,#4R,RYH M=&WM7>MSXCBV_SY_A2YS=SM=-S9^ J83IM(D/4-UYU$AO=.[7[:$+4#;QF9D MD\#^]?=(M@D/ R8AX>6NZF[ LJ3S^!U)1T='9[\->RYZ)"R@OG?^0965#XAX MMN]0KW/^X:)9;S0^_%;[Y>Q_).G'Y_MOZ-*W!SWBA:C." Z)@YYHV$5AEZ _ M??:3/F)TY^*P[;.>)$6OU?W^B-%.-T2:HAE)L>0IJQJJZ=B5=D4RB5Z6#*?5 MDEJ$6))!U)9E:2VL*=9II^I8FE(N&T12+)M(AEDI2=@JM253KZA:VW*(8UJG M3K745DRS4C%-7=.-EJ:TM):AJ175:3DMC$NJ:+<; LU MQ=4!X'4P;A_7NB& M8;]:++9QT))]UBG&#XK0:;T0%QZVF$O'19^>GF3^BRBN*8I>I%X08L\FX_+! M=.DG/2FK%G]< M*M@C3LA\C]JR[?G1Y[(2!(>ACUX34[^G9>",DP+ J9%6N__/++64A#E]1 <%(BGK-B]-M9,:JY MY3NCVIE#'U$0CEQR7G!HT'?QJ.KY'H'VZ;#*"Q(6?:2.0SSQ$9[? (H9M:/F MA^$]:9\7; FH]G"/UT1H]1(+CS 7#NOVB_ M[COCQLI*H7:I:.C''XKV\G8NP#8ZW#Y^<7%G7+5:J+6Q&Y"Y>HO3T2C3WW$;< M9. /F/@FK%LU)DYTG1.7_$X$!Y-OU.'?VY0P)+I$4G%6;WR=UI+9EVO)3].U M]X$[OI-\ V&Q\!(&FQJG1U),21M7]?QLW$UG0='D2?(]::0X17EPW8F^.M#8L.]2FX;7I->")AP*3\4X78A'IVHS!)+X.W47!\%MNQGZ]L^+ M(0T*M:1(W>_U?$\\B.HY*Z96/^;$N!?[(1M]#V4#X*PVB4=]=N.')(!1Q[H< M$."+>9 B,@Y!1)IRR"(R]U]$ARR>TOZ+Y]G(E0]21.5#$%%BY"H'*:+*_HOH MD,5C[;]XQD9.5U6YI)EW!-967GB0XE*5 Y.7HARTN-Y\+?].UD]7#U,^^^AD M6#2!T+7#E-$!.!LB^1B'*9^#\#0D0Y*ER9IYV&/2 ;@=)N2ER@^Q<='15>,F_ M^2+K^9UX7[Y'/:E+> Q,U=#DLMD//SU1)^Q6547Y6T$4K9T%?>S5SEJ,[]-& MGZ-ZYFKC80T2])MA.ZP&@UX/L]$G^*<#K81^OZI#]9PN";NTXU7Y:$18(6H@ MJA], >P&TR6@[*AC0 M_Y*J6H%6Q->GB+ RU,.C*A)"58V3]OVF\7!UB9H/%P]7S6FZ)BC:E=XVK^K? M[QL/C:LFNKBY1%<_ZG]JWU]>-9K-Q>[-%$K1,)/R)@R[U.J'OG:)+ MN2[__5>UI'P"E!K67-\WW$-KIH-&:@>C#FV1CTJF;OY[V9\5-$Q@T=HA+'ZY MO;]&V4-9DDB_*$PIBF0!ZU:1OLZ&L:#M2?,E.I>KTPJ2C$SJ!*;R_NKF =U? MW=W>/^Q.[[/9R;L!"P;8"U'HHR:Q>?!?) 951SY#JGGB?$1^>^?M/8^\A?X/ M& TIU'HUM+O8ZQ!T88?0?:1:NK&[HDG'"I^R\;[?D[[/0G22?"<8)FTD"!%Y MA.XA)AX3YV/U;8"=C?\O,*AW8A9Z%WMR-81UC(!)!/HD$ACA #7[Q.8K6@=1#]$P0/4N+/X(^YA%)J5=T_/]U/8= M, PA;KDDZ4'+9[ REZ C+NX'I)I\^)1$OT?1_9)X*5D7M_PP]'M5OO)^)"RD M-G9CM1 :$CV.%^66)5=,G:_+0P9_G:3A>,DN0_^*\[]KBEQ6S=1'BJRF_KZH M*E6732/]E76KTDRY9.EK5;7H=TU6#6TCG=)U65>LI545!>LC]H. N1J<%_1" MZD&'XNZ66D%&'SO\G%55ZP^1FF:MYI35[[^_F8Y\5&L>M6AXML]@@B:.U0BO M8MT?>"$;16/<'A$V%8N;_" M#[N$H?\,& T<*KP9VYOX9^L[S/7IY!@Q,Z7/8;VO.LG/F]$@V ,5Y,,-BHQ, MKGT'HGV-^R:ZZO5=?\1WI'=;_Z9'.W3CRVEJ*$:SHEC-SJW*T_:+M^CTR^CR M>>&Q[?B_;U"?.CXB7JAI"KKUT!\XM+NGZ)O_!..@^(*:(2,DW*'-JK=E3QT^ MWK('_VF\="H7:I>#%C2 YDZTGZ[AMYYN)5J?S:_@XH4;?^UY\599N'C;)3&D MNZ#024PR=TOV&4Q6:!^[B R)/0CI(_=6 G1)\!&=_(OV$5_79G)+[A(2_R^[ M%L2"Y_Y9?RQ?JU#3S;GL#VOH%E?:"T;P9"8&?JY$?46=WWP8JNZZOC>SEN0' M( P=EA# B^SJ..U K&Q%>(L4]-E9_O=?*YI:_A2@D+BDSVE'GB#^E,^RW0$? MWA$&1@/C)O3TW1VK!G>1KN=8M2JRI:0_>J&W<-->N;>9XV5<9=_X(;KH\X@[ M+I8-K8.W2F?Z9/8+C#()<'"1[Q&B> M*W/SJ?0]\2TAN]XE]D^15 OW^\R'P8=:/+I1U6RY^VW M =0##/9&R;,VV /_B;_'';64K_""ZCYMT1ARV2QM9 ?#TF7%,%YCD]9</&J)I@.<&C3(7$DD0QI/"QK M?*5JE0WCT]O[>-_#&YK.QI@Y0,,D=U!_(@[I?@ 0,C0SAMY,: ^/Z#E1RZC^ MY1YINB)#P8\9#%L.S1R:M-KT14@^D'4-0PGOQ&I!RV?.H%[,FGE0J@8& M.S6!RZDXNS$J#= P43('9@[,;,"\8X2/ESPAGPBVYK,W=MMN\V7K*H :1P%0 MX)!D3[!HY0BJ&HZDG;0^9H-K5#8'; [8%P&V$00#PM:"K9G#-A6V.I&,$SL; M;..RV6"[9*4>?.[QGCNT^&P*A553GE_!K(U&($_Y1P&Z9G5>P^X5' C<_&#UANQ]DSL<2+O"^$$6<* M'O'Y%*2*42WVQ@ DJFOMH>R#KU>OR&II^9"3.8@6.E"I;"9>U8*!<'E5>Q#H M.1MXG>Y.?N 9QJ/3-G87V?P4^)Y$I66DCV&Q%](<]5J^>U"DW<1'*(3D2#)T M@MUXZE+XY=FXK+-)$!L*[@\'ZA%8=>J@A)3]XLB\5X9HB$%[,N?1*'&MJ MCN/%+#:RX%C3.(ZADSF.E[$O'<=Z@N.+G$VO [*1 WDQB\U,0#8+-8VGW,Z! MO(Q]Z4 N)4#^G+/I=4 NYT!>S.)2)B##XD25U45 +A^OAI96 ]F*@9QSZ74X MUI4(6#34 M6@WD2@3DG$NOQ;&5XWA)I*&2!<@&/R"[<$0^9A6=YE\JD@TU0?(1#\GI>K8N ME@TMQ_(2'JN9L*SSV?4B;]=18UE=C64CP?(1^ZW3]6QM+)LYEI?P.%.(F%'B M'J_R@I@0?2X)RQ'IZ.JP+Z,<8SEGTVNAG$=W+>-QIO N@V>V6>B\UA?GW3]\ M'5T=WV7&\5TYFUX+93,/\%K&XTP17J;& T,616KJUA'KZ.H0+S,.\=*M8UXM M;R3&R\QCO);Q.%.0EVERSY>YR/-US%A>'>5EEA(L'_-J>2-A7F8>YK6,QYGB MO$P1Y[5HBFUL..'__O(O'A'/.XO)%0KU(>ZK6,QYEBO4HJQ_(BSY=Q MS./RZF"O4ASLE;/IU5#.H[V6\3A3N%?)6!8E8A[SL+PZWJL4QWOE;'HUE%\3 M[_62'$#OG?:EX3D\%Q)!K1&R1;[?'@92G[I$7.4SDXR7!@BZ2(#@#L]>T6'^ M4]CE*97Z/$$O!GB2-C0A[LF,TH@J9I(I9B:':'0KL(Y.^/4@Y4\BE6A2&)H! M'O?Y#9L\R7*4ETEK25I*76E7#8\KY3F:GM^;J%9>F6D]SI&_I=3+5PM8/.YV MQDYM+#W9BZZ$2*CX71!1CVA8F9FL5%Z9F6P;(IG7F%V$YO:%DE&>+IQNAOL,%*]IR1[SQ)PI- ]L!#8L[E>8EM1/!W:BG1H^Y#O$EZJ++\=(FM-E;)L::^Z:&('DS,NN'DJ)+WH=C!- M5C1Y/_-.II-V3X*!&XI+>V[!.L;9)L'&H2]C\U?WP1Q/79*XUL409D(_6'68 MF%B;A1"7XF&(8U['DP M#MGB\@J067O@NFA$,!/R:OL#!@/97P-QY3N,7@'H5_28]W!B.&.1S&5T ;WJ MCR^L>*9@KNA,/RAOFWDTZ/).\KEME[9HB, DJ7P4%%/8^H QGLCT/KI4! ;% MY (..:.T-RY:(^,0N6^7J>=&_55&W9(5]:",>HS'X,7V>DM&]<3YB+[!U)Y; MI%D:WAV'6LE:%X>J(5LZ 7JC*I3MCM!8 M:R)<1_?9'>+-YYFOJHV!$JO^6FD>=TVTER2P&>VGST/#\9(O?JZ9=OMM##'P.NJ<0^SXKO&JF*GR4M GG/2%>Z(E M*,BP'59)A+M/6^\@ZC+NYHO[8UFJU!YIQE\&3(,]X'_ Y&X("LQGJF=%/+N6 M/T83L5G-)+I&U%W6S*UU,*-FWDVMM& B-+.P=#!?34ZN/1?H\?[-T]/5656, M-;0XU6R_H1E^*]+%90!U'_J#[G"'H ;?T01]YCS5_#2@35]H$&7=%3T6A^^E-'F?@CI"-!WQC M1KB7XKMJH9D6+ M!/O# ]X1?K$6ZV&WSO2->D;# <8$N863@P3NB.CP(NS[C MOKAYC]0;!PH8"$MFLF)MQA\FJMIG[5339LJQ= MXY,%YG%Y5>F+*]5E93OI^D+Y5FC(N,Z:6 M61D<3"^W@4N<2)LMEINCG/3=I"DC)C^/]H6@[0II>\Z98E!$7S$C'OHFHSO, M?G:IZZ99S[VG]!*'I#KC=SMJW3QBVWF$I+_TLKB=&U,V8JV.4 %RTH^9]'U M]M60V .Q0?(/:A/$-](H#S@5T9'U+B7MB9C6VW8;"K$,$5)O?(OXH@V&/-I^ M1_=G%AR$^O%'XW/C 35N+J]^I&C"/CCS55-6-Q1T9LGFAFX3+ZNR55K>J3Q\ M;0<)S,/7\O"U/'PM#U_;K_"U7#/S\+4\?&U_P]<.Z1ASL>4[(_@/<.76_A]0 M2P,$% @ ]36W6._UT^[- P ?1< ! !M9'0M,C R-# U,C,N>'-D MW5A=V)UI,NUT)NUVTG2V;QT!%UM3D*@D8O??KR0@ MQ#%Q3+,SI9N7@'3.Y1[=P^4F%Z]W16[= 1>$T:7M35S; IJPE-#UTOYR^Q;- M[=>KL[.+5PA]?7-S;5VQI"J 2NN2 Y:06ELB-Y;<@/4/X]_)';8^Y5AFC!<( MK0SMDI4_.5EOI.6[?M#"VEV^"+PP3>;9'(4PG:$@C6,4 T0H "^.(C_&OAO] MM5ZDD>_.9@$@-TH !>'\'.'H/$/A=.[Y691"&D8FZ$XL1+*! EM*&A6+G5C: M&RG+A>-LM]O)=CIA?.WXKNLY7S]I MW$,7D$K.*$DF"2L<+=<-_6F+UK'(D>B$"HEII?4?OZP>Y MR/60[]D6EI*3N)+P5I7@"C)($3A&X.K,L?>ZD*!F7%CW@9EC$)N=*H#7&I::JU$4.3M=R_X,>HMC\$A?(L]'4V_ 8Y^J\NG/ M5G>HY?T7.70^'I9#RWMA#KW&?ZT].&T"59 MVD*5(8?ZA$8L/X5LJ'Q%(93\'\3G.!XJ7E$@'ZA;$V_5OD72I7W)U+QA6WKM MR\W[(]\7\[@:W89K W856+GFQ[-0-YL@R[ NG,?81U$J >G?=&6N'UNZ(3>0 M(\0$YTF5#^?MFZB7UBRVI]_L]3W>]U']Y[F*V].7)7\VV>@A/&/3(*X MJL!WI]X'*&)="!P+R7&BI@#)*V46W3:7]M-X2G+E 6V4&F_FFH4R'6'IK3%! M6G&3B^JLE0I.9*7OWG%6E4N[AA,)A9HU:OC]H+-(68$)?:\V=:2NNQY1HS\% M)D,_/%E1#V=TJKRH.72/3FW3^0-W^->BXXQ, M57W^P< O>C!2-?>."J+A+NPXHU/5N&CJ#W=>QQFKJO 7WJ=PK.]3-Q^>/I7T M<$:F:NA4\H=,)/[L%^:LV>]19?Y8J__=M#K[%U!+ P04 " #U-;=8EJ]D M1A$+ "460 % &UD="TR,#(T,#4R,U]D968N>&ULW5Q9<]M&$G[WK^!J M7W>DN0]7[)17<;9BG-EY-8=:/3COP/:31QZ:_&/47,/JC[=XW'_SHS<3WN>VF MA#Q?7';:7MYTS?E%/^*4R]5IJU^[IY*I%&VV1($P1*802 !P1 (+SO'@.77_ M.'^:'*?&2"#412!264V\TYDH81G/+D%2;C'HI)F]?UK^!#^'$4YO-E]\?79T MT?>73T]./G[\>'P=NLEQVYV?<$K%R>KLH^7IUUOG?Q2+LYES[F3QZZ=3Y\VN M$W%8=O+G+Z_?Q0N8>M+,YKV?Q3L!*#[UGRZ\CT:=W/Z(I\Z;I_/%]:_;Z/L% M05^=PNBS9Y1O9'4:*8<(XT2PX^MY.GK^9#2ZU9SO8M=.X"WDT?+C[V]?;2-M M9OU):J8GRW-._&2"B!7\.QHWDPO)[ Z=M%!_BSZU90+*%7@_+V,=C(8 MTP4"Z>)5 ()'859,O"+&7:,/Q_QI+)(@^ZM)7Q'Q]MA5\;93W]14\-;0%= N M!B)3F ;H:D)=&_<>SA7(381ER"FDOFMG33R.[?1D@>^T_? MN*8+V5Q2Q<5" M_NUU]^0BPO9B4N^"4J>-7#=#Z.7/@LM2=49$4D"X(XZ241B28%+@N9 M[#8K\Q7+Q$K>.^X[J%]UJ!DM[?Y#;SET[K8RW[I+?3:3M; /IED>*-J:!">:>( MHL7#&84>+NE$C+/1>D8IU[DVYYL@:E*^*R_>YGLH,YM$#U+K-L]T7YXQGQZ_ M@UG3=K^V/ZG*T &U J7LU)1BD;,F,99+5R6"5PWN!%X$9%9\W#"#U(,O=7VC:1HKK+ M-4M<,D;+@I%$&:!$HNLGUAA!=#)29LF,T'%?EVL.B]!ARMLF559WN7:)BTNL M_9C7!.M"G"QU@O@@-$E2V8!393&)?5VN/312ARAOFU15U>5^PD2U\XHEPK"J M)Q(+?U*"/0E429JM1):)=#QP??LAHQ#(728\G:L3M1:<[H%)9>@/N=H(!@Q+,Y6T)P*C 9$\1>)- M3"18B4&">6$HVS>^[I!W*$S74^H.YFNM1MT#R8XW,09,]I/5AE#'$UJGDL1[ M'TC02H0(5"K!]R9^2]P!\CY,I3MHK[=VM8PIDJ[R? H^24SQ4RC=+X=.R/EH MB(:0M6=>.7CP3;XAXW ('J*\':S66[Q:6IYT2V 0M,N@%(EEW5MRS8B'8$F4 MWN(_P(I^WQ7)E8S#876(\G:P6FOUZI.YJ96Y:29SIKITIZ1#8%FCN2$P[T!E M9J*@>R])JD.]5_=2W@Y6]U[**EN.5CO1S_#<,0!G#HS#4)#1O*05.$\:20R< M):$4=7JC0?O #7CWI?UU?'ZGG7A[JZYBS_T^#@SK39M>SM)/OH>QW*Y)O9@2-U?F16;[_?G&-ONLNT6LUQL&#IM MKV9]=W/:)A@K&4!&B]$=81*IE2/6TTR\MM)KZ@2'8??M-X!X],S75G3%?OT= MO)^;"?QZ==MR!J8]=Y9D:\J&D+*$9B0:IHI*B9B9IU_:+/NMI-])/!"&]U1A MQ:[]'98S?_TJH;=I+X3?%@L[ZG0BML MB'=I@ECB:6XY]83X$X2F: \OV$L$ZBR8J._X%E"> OG.+TQ!\>T T%,=EC"*%EHC$. MB[#WI3U^#O=57<66?<'Q&G^=O+EH9ZN1 J-:4R&C*&PQ8P F); RF M=%D-\Z^;$A\]E8-46+-97\#\T35]#[/RT,K5;)F7S\?)<143#02C-4,#VL,<*VT&G9O[A3[Z)D=KLR:'?R"Z%T[:2(J<7;^B^^A:_QD3"%G:7%> M62(2*:0KN^(= 2V9I$"Q!O_20UY?YW9;YJ,G=J ::W;G"YPW'10;@UE/R_[T;-<2:TUF_([ M8+V:SZ^@NP\.$P#+0P#B@\8D0)5^E?9 E-")2FLCY<-JV*\A.#3FAZFX9OM^ MX7P@7F%@N6$\G#7]!,:."9&I"\1'COD"C^AZ1)+$6"4X)&XX2\,\^(;$1\_O M(!76;-P7,&>=+R\B>WUDS"/77 -68@GA2!H"EF. AJ:]P\2A;/(;UA=< M$_?HF=Q?>;4[]2N;>GD=+_SL''[U4QB'K)*5/)6''PPI6[5(D%1CUF>H%C(R M&8:%WUU2'SVI@U6Y@]M!RTVWXU?7?NQO\ <>EG-V,?M4FIO&<. M>,&5"T+*B.(F&$NI8+E&+VBG\$?/="W%[B!\T,K4+:Y3C/V=G[S"N'_];[@9 M0_+@$L=Z34A.)&B!A3G.UTG.@Y;142\K4+TA]D!('J+,'?0.6K6Z15060.>( M:=8O'$R.9:NMMB0X$XDTS!#/52C-*1&SS!1DC=;/NM0#(7> *G?LPQBT@K76 MJGC3SGL_^4]SN5@GI8(F,)BPEU>NEK>KEFU"4!XU%E((QQ@7PW*KS\L^$)X' MJW4'VX,6M%Y@?99*C?;SQ)^/P='$+<\D1L\P_^,:O8O(Q% ;J'$YI(')\YJX M1\_I_LK;0>-R!>N'DPUM(,SWSY\L#Y<_Y[W&2O2BLWUF2?YIOWV>:]S?ZQ*O^: M?Y39;PNY<:OR$8#OZL=>K9Z^E/.']YL,0TSWS?9_+;^FB!G-'0?,D@)0HQ10 MU@I +5)"8"4Q%"\?OC8"PZ*@%D"A+:",YT"*W %&.,).&&N8J#M=S)=_?5W] MH^3:9A[>;IZ_O[S]]^G3W696+NU7Y<(\A)/?[UB]VS3]?M/]$ MZM9("'%?__70=#UO:NB[1??__/G-6_W>/DHP7ZXWOYU^OZPSU MUGO'E;6VJ/X']LU ]1% &!!T]WEM7GSW599MU5&N%O9WZ[+JYQ^_OVX5*>ZK M%O=+^U!]M[_9RW+R1RB[\Z.O>-E^>[+BU6&[F8X+5X%G,TY$7UP1O_VTY,U5&' M,:WE[$SWT5#MYXU=>N]16\N3KK.Y^?:%_VUF['SVXW(SWWSYWIC2KM>O5A^6 MF_+++"^T=VDX!X0*#*CV3HP3[X:PHUQ@H3B"=K8YO-,SNP1_O-V+KV5T"W@1 M@&S3PE#?W>I#J;>^S0NM_/IV'-]M168[F2^SG=1O[I_'%Z&4Q=6A+JZ*EY4;GI5GD-9Z5XHSZ_]VF.I<:RMOGM8?;SWCWH\F%2_@.J7^FUO[?#^XFOX MOMR/4I:Z1V>[%O=ZY6<@3QMPHCY7KAZ'P=FLAGV#6[5YH2^R56ELZ6>5#0 . M[]&CVVN5\5?ZRVMBU5P;\X8/U/]C/]E'9[8=058/(3,?;#4I9L,8UZNI;N:-B3^,@2>8 M*[G9#SO@V9];V?\[D@;,;G523ZPGT<2)Q!$TDFZ6AJ+;FB??NC) %+*=$>I] M?!)C-!3$WB@-;C^.<:)P_\(9:!3W2U9=4 .HI!AP2!F #C&8"RX+BU*,TU[0 ME8T3NB,%:S1.%*91\Z"I..,4@W\X8]&M2[;_ZW;M'C-4:VAPHP36@S@B@ MN&3 ,BM-[@3F?A+UT99J%6RIVJ6&O*K'L@/,%FN94Q$12=H.'09:L''TDF3, MD-A1EXB7636,;#>.5-/6H:5(*S>.MD8Q> E:B[>#_?B'FL2.GFYC'?NAM1K* M 8^&VOK975(4;\H;^9+^WIC']>S N42(4* 41H!*G(*A"XX*#373DAD M*')A&SI-8J;9UCF2G/U9RQV MXNV?+FB7FT"=KE6:.:E9I78X5QLUDL_#9/1AC$P&&@0]3K!1+&NNLP^K7KJYM^H^@@C'Y;45DM:\39:B^2!NXYN58UEMW#6P+:Q6:]_^29B>W] M3\+$7GA[)O8W#'=XOY6VZL[Z$58$?U<=1I:_.N=?+XZ9M#3/@3'<^D6[$$!J MAX%%4CAA.35.#O5Z[6*N[/J\8*"/)&=;T5DM>[C_ZU!3OQ,-P![G# M?EA1/K&CV\D<8S^T8^\XH'6DBUS(]?I75S/]A]6CG"]G%C)KM?>,UHC"D[*@ M0!)) '340BF5(&P0*=M%7)F0M8BMTX+*P0S$#G6$2W$!O&(@TW!^V M@AG+(5X*F-8CM@*\<(GM+<-]XMO58J[GF_GRX6<_S2WG!E]U>FW+/ ;"]QN.=K4$:_QTN#&+CI'( NR+^U M@XCR:PW=3>;/VJ$<^[&.5N,<#5&QWZ5'T$(,'5!$>2]&* <\1PAHFZ.B*+#) M^<"57I^H"0Z!"M9\"$03#X$.VNKFVY@:"&1>R\$%%2,=\#R_+TFG.C&:&/>%9)CXRW/554 M_Y1@'/AA!BH6>7P,;B.P]$CY=3@Y7U5=EE9NZ2M7T(O*Y!O)]C[&1:+*'!5.PQ, M$(6:1AY%FI..)J-)T_"/B='X]U@_]+TT]O-_VR\S!Y7&1B# :2YP@(!%$&2.6,+;!C M!8X)MIXR"P3?Y;@YT#HR"R0A ^06V1_C)'Z,D/1QRX2/J^5Z).1YW#['(R2_ MXYJY'6P?KZ\+55AF),@-PX!"I(& ''KO+@3CC#+FDG([V%2Y'6TFAR7F=K"T MW(X8_$G[8X=,!C96;@<;)[_ -6>D7[9-&+C M:YO6_KM]J$RZS+DJM!6 "5.13N1 *$9 GF/-G"MTP>C@G:_CGJ^]];65E6V% M!6Q]G: ?L/<5BREP\VL8G+#-KZ:AQ^U^G?0TW?97$X"3_:_&!B/5:>"[*1#- MH7(:,V"4R2NWQ("@U "M),0YLH5)FR[O!5V9,+ U%1KSQ"H%/&FZ'(-_G.DR MYF/5:>"C3)=C-#%RG8;V5R&]3@-/FBX?'K]MG08>-EV^:!\1-&;UA]([_A\_ MZ_?^.[2_R$<[DX0CR4P!("7<&R6I@:(& 2*,GRI#E3LXJ'A,FX K&Z.]R&PO M,ZN$!L2.->FDWYFG(@TU.T$@PT+(.I#$!9$U=3A=&%D'G)- LJYV\=1"6+V; M;Q9VAAVV2FL_!Z9Y=>9%-."(8V"ERK6EUB 63*M]YU>F5"VC"@I&^#_4?V9[ MZ>&<.BAC.)]B((9Q*11=%)G.8201Z=#9Y"0ZA]%$H(LVX>3YA^]G8Y=5@L*' MY7Q;\W4]$Y ;)60!F*9553-M@2)$@ +F!=%:()P/9E"CA"O3:"4*$XU]S@9L3H!';.KNV$XQ:I2RHO?WJ^6]I^96)58O+:GG95N!P4EWHH9]/ M*>C"J!0 +(A&;0BB&'31V63D:8-QS)O6-N&4>5?*JL;[VR^/:K68898S5#CE M%T>65/45%!!66(!SPJB$3#DT.(;II.=K3^:VLK*ML.%$.47?SY)H3(&SMV%P M@NC1./0H;ISV-!DQ&@$[H #H^[B@& M_&AQ1QU?>%+/-L9)""N1 ;B7W5D<@H)0N "E@H2747-#@6F0=\J8Y\C\9PLNL'D1U$+X_ MUXO)A^E68[]S'UDY859J#+U$E2\;@#:ICEE7_Y,7-!L MJFRV9#'QDG,/02S M%IPS15$!E"W\7*/ 59Z[$]51*B',?U:H07$&?8*N?HJ*6Y)RHZO=GVLJ:,Z1 MA#]AWG&4@II>[?Y< VE)N3>K=A^DD>2DW-BR]^>/WS0I=W#9^[;V(U661N@. MGM7[533'4F *J!4YH-144=*, E:P7"DG*2)QUW.TR[RR[4*M-W5$KI4Z]1=G MQA*U,HY%(ZBJCPQ'KRK=H*7$JM)IVAJYJG2PUM*K2K?C#ZTJW=#3;:M*MT/K MK2K=\6AR';_7Z_4'6YY4\V,:V2H^3NN< "J5]#,[(0#BC"*#+<^'7Q;6)^S* M%O*BMMUV ..4]KO47/\2;DQ]A-G&)%6D5/MKQ3A&S;_+SF]5^:\59D?]O_9G M8J+ /]KR>[7>E%)O9LP2:+A% ,J*PQ92P#E!P.;6.2<1HFAP.9*3GJ],V%I6 M]B0?[%U("/@Q]'X21@,*8]P6RY][02-5=6\K3YOWGGU/=+:5G>V$AVY/-FMJZ+9D,OZH[F_N=>,>Q M$]SE3F-W\_'6[CEFI\LJ) I';9$#)*A?P7/+ &<& N@(I\0: 25)7;R?"[WZ MZKTMW7F,U?N%!N.7[REZ&7/][L=QA07\A:+25_ I"KO&$CY(<:.LX=LT$+&( MO^CJYJOX-G!#EO&MSXY0?6:?LR2Q)5IB W*I.*"4..!G-;*JFXH+BQ5V(L96 M3IG;1MKO(([+;4O(:[M%3MLXZ6PCI++=,HWM:AEL"=EKM\]<"\E:&R-CK3&P MA.X#S@H"P%G[%YX6<$:C3/RFF?OG(/HR]R_: MA^\H[R\W?.;J)F1]F[%RZP>Q]A[MTV*2MR[3538R'NWX8I+W[OMT$#HWFU35[?= MN^T U[MWV_5L^$3B>_^:F.I5^6DA'V86%411RX#5 @-JJE!ZZS1PT'$BD2F8 M&'P8?=+SE:<2!UE9)6SX7.(4??]D(AI3F 4;""=H.M$X]*CYQ&E/DTTH&@$< MSRB:&X118G\W8YV[4O5U?$GC]Y_GZUG."R5R!OVBOV" W[E:?\#L<%5/\T7^PH>0BK!'31 X#J]PG.5JT("BG-F(*TN!0\L]OS<^95) MN8LEJN0%5S*YT$._.TM!%\:[ & 1@5&7"!*BH8XZFS@$ZA+&9=Q30YM(RLSM M^IU4"SLC3G%,G0,$.N_1!,P!I]AY^EB)J1 :81[$EWW/4Y#%R\K^K*4-=%Z7 M^ ?R) 95!$F& JGR/G@X_EQZ&E:J\C+6*?U0/PTH'U/9!XZY#E0U1V@F&A$\EP33\TP1IX*F(:,SS(#BXLWZF0H^^*11A%O*,@(NC4C M26#:68<3DZP9SB6_6MJ-5 ZGV!]T:DHX)! P5WBGIS !RAJ_IA,YHTIB2?D@ MBO4)NC+54&OY/5PD%H,ID@XS8_"'$;"U^$LQ5CF<8I13RAA-C%P.9X!&TLOA M%$G'CX?';UL.IP@[9KQHWV:ECO7NIPQ_???5_A/_CY)K^]U7_P=02P,$% M @ ]36W6!;<^@??"@ ^%\ !0 !M9'0M,C R-# U,C-?<')E+GAM;-6< MVW+;1A*&[_T47.WMCC3G@RMVRBL[6ZYU$I>M5%)[PYI#CX0R2:A R)+>?GLH MTC8E'RB"#, +RQ()HJ?_^3C3W6C@IY]OII/11VCF53U[=L2.Z=$(9K%.U>S\ MV=$?9[\0>_3S\R=/?OH'(7_]^]V;T Y=?\Z?YH<4G&R.OIH>?C-@^.OQ>)H MYIP[6;S[Z=!Y];4#\;3LY*]?W[R/%S#UI)K-6S^+Q<"\>CI?O/BFCKY=J/[# M<8V^>43YBZP.(^4EPC@1[/AFGHZ>/QF-[N1HZ@F\@SPJ___Q[O6:R2FDMJEG M53R.]?2D''%R6B,1.-;%9]O;2WAV-*^FEQ-8O7;10'YV-$TM*7-*%1?%X#_O M/G?RV>YE W.$9>'G&WQA^?%B9(LQP$T+,YSHA6,K$Y,ZKATT*;+6GSXY\0$F MBU?'":KQXJPOPKQM?&S',3&JHE'$9U.8"H+XY!UQGFDPB5/MZ+K+9:N?5Q?SFE+YHXJIL$#:X<*WN^B0^F=YW9Y1$G ME[[!$Y%X44W2ZM.YJ:>[F*VVWH5V=S.#XST:H=L9F@;2F[N)^:9W"]=:7%!A M<>2VDWXU)^?>7X[?H])0%MS3B9_/?\_OVSI^>'%3S<<.A.6[DB 23M?O?(9B1\.IC]$.DQNO0^E!X#,E^-_ M64]]-1N'S(0O:GC*!.J2./$J ,E&9\@11 YVQZP\'$4_D.QX>NN=:CT$6NKI MM)XM'/@5I@&:,154*.\44;1\B8S"+U'2B1AGH_6,4J[SKF&Y/XA^6>DZJ_./;&S$ A\X"SL5LL=EXX$?G*[[H6P6"?$E*%+")(X' MX@5"+IC6AC/,H))[+!#W;&P$A#@T(+H(.1P@UGV(6JJDLB%%"%SG<%>U2J!. MX$7@1D5GS>-@>#P(\K! V%[ X4#P>74S2S]DC)8%(XDR0(G$#8Y88P31R4B9 M)3-"QVVW"?,(&-1AP=!-R"$!L5K=[-(/+C$98UX33-10'.HPF0]"DR25#2@- MBTELNTW81P"A#PV(+D(.!XA[/E#MO&*),$S1B<0LGI1@B 2J),U6.2?T-MO$ M8T PAP7"]@(.!X)/JYM@[%AS]1::B(*N5CI,O&WF$9/QA"(91#QPC'\L9DY< M<,Z-_%$]^C'V-H+$'A8DNQ-XH-!0NNX2AD2@J8\$0J2E1&R(93D1D2)-7%D6 M0Q=F[IG;"!EWP,ATD7"3Y&3X)\2;(26E^M)R9?(R892>TG$6YZ$5@ET?/1B M<<_&9C0,O8ZY4R6'0\2=#W+I0\X.(K>)1,84D3($8G.TA$4O)4A#S6,SU+7S M;T;"@54QMU=P.!1\WO &,JV M#2B^8F\S2@ZNM+DKA0=Y*40X=GS?J8!Y6++:$.IXPJ^"DL1['TC02H0(5"K! MM\;F@;G-J#FP.NC.]!T6-,NM4])5$D;!)XGY5PKEXK/#]=+Y:(B&D+5G7CEX M] )SS\9F>!Q<9;2+D@/M$@=6 M)>VF9(^KQ*?6MMO7L]),O>J@A=/]>&#:!?M=U/-\9N6OUVJ&K/;*S:\,_PV#$ 9PZ,PV@HXSHGK<"O#(TD M!LZ24(HZ[3O1\*6UGEL]=S!S]0YD',CT8U1G5++WT+8R=BRD$ZDA,$1=, MF21QR>'W0FGIG>8ZW"]M;LG!FMF>%X3] +&]L /9-&+=7-;-0I5%Y^MI?35K MF]O3.L%8R0 R6@R-T2TBM7+$>IJ)UU9Z39W@T&V]V& 0_?1P[8F:78L^"(9^ MJ2;PV]5=%Q(P[;FS)%M3>A-+L=](_!*HJ)2(F7GZO5L--@7FL\5^&KOV2L>6 M<@X"A3-_\SJA<%6N[NY96SHBE&$! RXBLD2F$6I<%XLL3C!*J0?+S ZX^(;Y M?AJ^]@K)+H0>!#$O4L+YF"__*_*P<0#!HK",*)-<*=I18BW5)&1M )GG47:[ MV^Z;IOOI!-LK*5T%'A(EI_CK[\U9?3T;"XN6/,LDN&B(#%&2X!W^9B@WEJ7$ M'-\=(Y\-]],B]G<0LJ6X@^+C+HP:2^FMY]83X$X2F: D_\82P;R5ABN:^2[B MUG6K_?2%_2UD;"%KSU@LA_P.SE&.,0?'M -!3':8L(=RXQ[/C@@K\T:TZD<$V971@@M$XVQ MX_W[7UCKJ;-K7P!LJV//\_\&WYV\O:AGJV2*6QJYY$"HUI3(:,IS05A 40V M!N/EK+IM"OT_YN*AS9[:N?8$14=->R;B;0,%9YC% MQ5,@SLJ3A)K?B!(Z46EMI+Q;D>)'(^BIH^OO MH::;WGWO.Q"O<.^\93R<5>T$QHX)D:D+Q$>.X12/N$**)(FQ2G!(W'"6NNTZ M]RSVU-NUKSVGBYX]LW#6^/(8Q?>WTU!/QCQRS35@>IUP])*&@#DV(-/:.XRK M2HM\MXOS:^9ZZN;:$P7;*SF0Y>#53;SPLW/XS4]A'+)*5O)4;K0TI+0JDR"I MQH#:4"UD9#)T"S>^9G4S( ZECME9UT&4MU]-H3E'KO_3U-?M!>Z!EWYV._91 MFY3*@SR!%S=R<8@RHK@)QN) 6-[%1=6O&M^,DD,IM;@;&H51%.^LZ M""Z6U_G>UO/63_Y772YJ_530! ;SJ/)P[?(<[=++".7Q,4(*X1CCHEL<^FW; MFS%R*#72'6G<,RDO,.5.)>W^9>+/Q^!HXI9G$J-G&%ISC8N@R,10&ZAQ.:2. M2*(E^?7C^9/E&^5$>%/_\R?\!4$L! A0#% M @ ]36W6&']&?(>EP 6C,. !X ( ! &5X:&EB:70Y M.3$M9GDR-'$T96%R;FEN9W-R+FAT;5!+ 0(4 Q0 ( /4UMUC8KJ.")A, M 'GF 0 " 5J7 !M9'0M,C R-# U,C,N:'1M4$L! A0# M% @ ]36W6._UT^[- P ?1< ! ( !KJH &UD="TR M,#(T,#4R,RYX XML 20 mdt-20240523_htm.xml IDEA: XBRL DOCUMENT 0001613103 2024-05-23 2024-05-23 0001613103 us-gaap:CommonStockMember 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotes2019Due2025Member 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotes2020Due2025Member 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotesDue2025Member 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotes2019Due2027Member 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotes2020Due2028Member 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotesDue2028Member 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotes2019Due20311.625PercentMember 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotes2019Due20311.00PercentMember 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotesDue2031Member 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotes2020Due2032Member 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotesDue2034Member 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotes2019Due20392.250PercentMember 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotes2019Due20391.50PercentMember 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotes2020Due2040Member 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotes2019Due2049Member 2024-05-23 2024-05-23 0001613103 mdt:SeniorNotes2020Due2050Member 2024-05-23 2024-05-23 0001613103 Medtronic plc D02 XH02 false 8-K 2024-05-23 L2 1-36820 98-1183488 20 On Hatch, Lower Hatch Street Dublin 2 IE 353 1 438-1700 false false false false Ordinary shares, par value $0.0001 per share MDT NYSE 0.250% Senior Notes due 2025 MDT/25 NYSE 0.000% Senior Notes due 2025 MDT/25A NYSE 2.625% Senior Notes due 2025 MDT/25B NYSE 1.125% Senior Notes due 2027 MDT/27 NYSE 0.375% Senior Notes due 2028 MDT/28 NYSE 3.000% Senior Notes due 2028 MDT/28A NYSE 1.625% Senior Notes due 2031 MDT/31 NYSE 1.000% Senior Notes due 2031 MDT/31A NYSE 3.125% Senior Notes due 2031 MDT/31B NYSE 0.750% Senior Notes due 2032 MDT/32 NYSE 3.375% Senior Notes due 2034 MDT/34 NYSE 2.250% Senior Notes due 2039 MDT/39A NYSE 1.500% Senior Notes due 2039 MDT/39B NYSE 1.375% Senior Notes due 2040 MDT/40A NYSE 1.750% Senior Notes due 2049 MDT/49 NYSE 1.625% Senior Notes due 2050 MDT/50 NYSE false